aspn-10q_20170331.htm

0001564590-17-008901.txt : 20170505 0001564590-17-008901.hdr.sgml : 20170505 20170504190219 ACCESSION NUMBER: 0001564590-17-008901 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20170331 FILED AS OF DATE: 20170505 DATE AS OF CHANGE: 20170504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ASPEN AEROGELS INC CENTRAL INDEX KEY: 0001145986 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-LUMBER & OTHER CONSTRUCTION MATERIALS [5030] IRS NUMBER: 043559972 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36481 FILM NUMBER: 17815672 BUSINESS ADDRESS: STREET 1: 30 FORBES ROAD STREET 2: BUILDING B CITY: NORTHBOROUGH STATE: MA ZIP: 01532 BUSINESS PHONE: 5086911111 MAIL ADDRESS: STREET 1: 30 FORBES ROAD STREET 2: BUILDING B CITY: NORTHBOROUGH STATE: MA ZIP: 01532 10-Q 1 aspn-10q_20170331.htm 10-Q aspn-10q_20170331.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2017

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number: 001-36481

ASPEN AEROGELS, INC.

(Exact name of registrant as specified in its charter)

Delaware		04-3559972
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

30 Forbes Road, Building B Northborough, Massachusetts		01532
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (508) 691-1111

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☒
Non-accelerated filer	☐ (Do not check if a smaller reporting company)	Smaller reporting company	☐
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 1, 2017, the registrant had 23,508,417 shares of common stock outstanding.

ASPEN AEROGELS, INC.

INDEX TO FORM 10-Q

		Page
	PART I FINANCIAL INFORMATION

Item 1.	Financial Statements

	Consolidated Balance Sheets (unaudited) as of March 31, 2017 and December 31, 2016	1

	Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2017 and 2016	2

	Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2017 and 2016	3

	Notes to Consolidated Financial Statements (unaudited)	4

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	11

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22

Item 4.	Controls and Procedures	22

	PART II OTHER INFORMATION

Item 1.	Legal Proceedings	24

Item 1A.	Risk Factors	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	24

Item 3.	Defaults Upon Senior Securities	25

Item 4.	Mine Safety Disclosures	25

Item 5.	Other Information	25

Item 6.	Exhibits	25

SIGNATURES		26

Trademarks, Trade Names and Service Marks

We own or have rights to use “Aspen Aerogels,” “Cryogel,” “Pyrogel,” “Spaceloft,” the Aspen Aerogels logo and other trademarks, service marks and trade names of Aspen Aerogels, Inc. appearing in this Quarterly Report on Form 10-Q. Solely for convenience, the trademarks, service marks and trade names referred to in this report are without the ® and TM symbols, but such references are not intended to indicate, in any way, that the owner thereof will not assert, to the fullest extent under applicable law, such owner’s rights to these trademarks, service marks and trade names. This report contains additional trademarks, service marks and trade names of other companies, which, to our knowledge, are the property of their respective owners.

PART I — FINANCIAL INFORMATION

Item 1.

Financial Statements.

ASPEN AEROGELS, INC.

Consolidated Balance Sheets

(Unaudited)

	March 31,			December 31,
	2017			2016
	(In thousands, except share and per share data)
Assets
Current assets:
Cash and cash equivalents	$	11,228		$	18,086
Accounts receivable, net of allowances of $83 and $93		17,248			17,535
Inventories		15,132			12,868
Prepaid expenses and other current assets		1,192			1,697
Total current assets		44,800			50,186
Property, plant and equipment, net		82,719			84,394
Other long-term assets		97			89
Total assets	$	127,616		$	134,669
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	14,169		$	13,065
Accrued expenses		4,112			3,987
Deferred revenue		789			1,043
Capital leases, current portion		20			35
Total current liabilities		19,090			18,130
Capital leases, excluding current portion		—			4
Deferred rent		1,082			971
Total liabilities		20,172			19,105
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized, no shares issued and outstanding at March 31, 2017 and December 31, 2016		—			—
Common stock, $0.00001 par value; 125,000,000 shares authorized, 23,508,417 and 23,369,838 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively		—			—
Additional paid-in capital		534,346			533,088
Accumulated deficit		(426,902	)		(417,524	)
Total stockholders’ equity		107,444			115,564
Total liabilities and stockholders’ equity	$	127,616		$	134,669

See accompanying notes to unaudited consolidated financial statements.

ASPEN AEROGELS, INC.

Consolidated Statements of Operations

(Unaudited)

	Three Months Ended
	March 31,
	2017			2016
	(In thousands, except share and per share data)
Revenue:
Product	$	22,326		$	32,286
Research services		676			535
Total revenue		23,002			32,821
Cost of revenue:
Product		20,470			25,992
Research services		311			302
Gross profit		2,221			6,527
Operating expenses:
Research and development		1,576			1,310
Sales and marketing		3,110			3,062
General and administrative		6,587			3,913
Total operating expenses		11,273			8,285
Loss from operations		(9,052	)		(1,758	)
Interest expense, net		(26	)		(39	)
Total interest expense, net		(26	)		(39	)
Net loss	$	(9,078	)	$	(1,797	)
Net loss per share:
Basic and diluted	$	(0.39	)	$	(0.08	)
Weighted-average common shares outstanding:
Basic and diluted		23,257,541			23,063,471

See accompanying notes to unaudited consolidated financial statements.

ASPEN AEROGELS, INC.

Consolidated Statements of Cash Flows

(Unaudited)

	Three Months Ended
	March 31,
	2017			2016
	(In thousands)
Cash flows from operating activities:
Net loss	$	(9,078	)	$	(1,797	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		2,676			2,410
Stock-compensation expense		1,244			1,370
Lease incentives		(22	)		—
Other		(1	)		(13	)
Changes in operating assets and liabilities:
Accounts receivable		442			(2,291	)
Inventories		(2,264	)		393
Prepaid expenses and other assets		497			966
Accounts payable		2,238			1,508
Accrued expenses		125			(2,203	)
Deferred revenue		(254	)		(542	)
Deferred rent		(22	)		(15	)
Net cash used in operating activities		(4,419	)		(214	)
Cash flows from investing activities:
Capital expenditures		(2,146	)		(3,128	)
Net cash used in investing activities		(2,146	)		(3,128	)
Cash flows from financing activities:
Repayment of obligations under capital lease		(7	)		(23	)
Payments made for employee restricted stock tax withholdings		(286	)		(82	)
Net cash used in financing activities		(293	)		(105	)
Net decrease in cash		(6,858	)		(3,447	)
Cash at beginning of period		18,086			32,804
Cash at end of period	$	11,228		$	29,357
Supplemental disclosures of cash flow information:
Interest paid	$	40		$	52
Income taxes paid	$	—		$	—
Supplemental disclosures of non-cash activities:
Changes in accrued capital expenditures	$	(1,134	)	$	484
Advanced billings	$	—		$	292

See accompanying notes to unaudited consolidated financial statements.

ASPEN AEROGELS, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

(1) Description of Business and Basis of Presentation

Nature of Business

Aspen Aerogels, Inc. (the Company) is an aerogel technology company that designs, develops and manufactures innovative, high-performance aerogel insulation used primarily in the energy infrastructure and building materials markets. The Company also conducts research and development related to aerogel technology supported by funding from several agencies of the U.S. government and other institutions in the form of research and development contracts.

The Company maintains its corporate offices in Northborough, Massachusetts. The Company has three wholly owned subsidiaries: Aspen Aerogels Rhode Island, LLC, Aspen Aerogels Germany, GmbH and Aspen Aerogels Georgia, LLC.

Unaudited Interim Financial Information

The accompanying unaudited interim consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes in our Annual Report on Form 10-K for the year ended December 31, 2016 (the Annual Report), filed with the Securities and Exchange Commission on March 2, 2017.

In the opinion of the Company’s management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and include all adjustments that are of a normal recurring nature and necessary for the fair statement of the Company’s financial position as of March 31, 2017 and the results of its operations for the three months ended March 31, 2017 and 2016 and the cash flows for the three month periods then ended. The Company has evaluated events through the date of this filing.

The results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017 or any other period.

There have been no changes to the Company’s significant accounting policies described in the Annual Report that have had a material impact on the Company’s consolidated financial statements and notes thereto.

(2) Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements, which have been prepared in accordance with U.S. GAAP, include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the consolidated financial statements requires the Company to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, sales returns and allowances, product warranty costs, inventory valuation, the carrying amount of property and equipment, stock-based compensation and deferred income taxes. The Company evaluates its estimates and assumptions on an on-going basis using historical experience and other factors, including the current economic environment, which are believed to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity markets and declines in business investment increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in these estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods.

Cash and Cash Equivalents

Cash equivalents include short-term, highly liquid instruments, which consist of money market accounts. All cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits; however, these deposits typically may be redeemed upon demand and, therefore, bear minimal risk.

Revenue Recognition

The Company recognizes revenue from the sale of products and performance of research and development services. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred or services have been provided, and collectability is reasonably assured.

Product Revenue

Product revenue is recognized upon transfer of title and risk of loss, which is upon shipment or delivery. The Company’s customary shipping terms are free on board (FOB) shipping point.

The Company records deferred revenue for product sales when (i) the Company has delivered products but other revenue recognition criteria have not been satisfied or (ii) payments have been received in advance of products being delivered.

Research Services Revenue

The Company performs research services under contracts with various government agencies and other institutions. The Company records revenue earned on research services contracts using the percentage-of-completion method in two ways: (1) for firm-fixed-price contracts, the Company accrues that portion of the total contract price that is allocable, on the basis of the Company’s estimates of costs incurred to date to total contract costs; and (2) for cost-plus-fixed-fee contracts, the Company records revenue that is equal to total payroll cost incurred times a stated factor plus reimbursable expenses, to a stated upper limit. The primary cost is the labor effort expended in completing research, and the only deliverable, other than the labor hours expended, is reporting of research results to the customer. Because the input measure of labor hours expended is also reflective of the output measure, it is a reliable means to measure the extent of progress towards completion. Revisions in cost estimates and fees during the course of the contract are reflected in the accounting period in which the facts that require the revisions become known. Contract costs and rates used to allocate overhead to contracts are subject to audit by the respective contracting government agency. Adjustments to revenue as a result of audit are recorded in the period they become known. To date, adjustments to revenue as a result of audit have been insignificant.

Stock-based Compensation

Stock-based compensation expense is measured at the grant date based on the fair value of the award. Expense is recognized on a straight-line basis over the requisite service period for all awards with service conditions. For performance-based awards, the grant date fair value is recognized as expense when the condition is probable of being achieved, and then on a graded basis over the requisite service period. The Company uses the Black-Scholes option-pricing model to determine the fair value of service-based option awards, which requires a number of complex and subjective assumptions including fair value of the underlying security, the expected volatility of the underlying security, a risk-free interest rate and the expected term of the option. The fair value of restricted stock and restricted stock unit grants is determined using the closing trading price of the Company’s common stock on the date of grant. The fair value of awards containing market conditions is determined using a Monte Carlo simulation model based upon the terms of the conditions, the expected volatility of the underlying security, and other relevant factors.

During the three months ended March 31, 2017, the Company granted 481,373 restricted common stock units (RSUs) and non-qualified stock options (NSOs) to purchase 320,571 shares of common stock to employees under the 2014 Employee, Director and Consultant Equity Incentive Plan (the 2014 Equity Plan). The employee RSUs and NSOs will vest over a three year period. Stock-based compensation is included in cost of sales or operating expenses, as applicable, and consists of the following:

	Three Months Ended
	March 31,
	2017		2016
	(In thousands)
Cost of product revenue	$	204	$	192
Research and development expenses		138		140
Sales and marketing expenses		268		261
General and administrative expenses		634		777
Total stock-based compensation	$	1,244	$	1,370

Effective January 1, 2017, the Company adopted the provision of Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU 2016-09) related to the timing of accounting for the forfeitures of share based awards using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of January 1, 2017 of $0.3 million. Effective January 1, 2017, the Company will record the impact of forfeitures of service based awards at the time an award is forfeited.

Pursuant to the “evergreen” provisions of the 2014 Equity Plan, the number of shares of common stock authorized for issuance under the plan automatically increased by 467,396 shares to 6,536,597 shares effective January 1, 2017.

As of March 31, 2017, 3,244,691 shares of common stock were reserved for issuance upon the exercise or vesting, as appropriate, of outstanding stock-based awards granted under the 2014 Equity Plan. In addition, as of March 31, 2017, 92,947 shares of common stock were reserved for issuance upon the exercise of outstanding stock options granted under the Company’s 2001 Equity Incentive Plan, as amended (the 2001 Equity Plan). Any cancellations or forfeitures of the options outstanding under the 2001 Equity Plan will result in the shares reserved for issuance upon exercise of such options becoming available for grant under the 2014 Equity Plan. As of March 31, 2017, there were 2,485,081 shares of common stock available for grant under the 2014 Equity Plan.

Earnings per Share

The Company calculates net loss per common share based on the weighted-average number of common shares outstanding during each period. Potential common stock equivalents are determined using the treasury stock method. The weighted-average number of common shares included in the computation of diluted net income (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, RSUs and warrants. Common equivalent shares are excluded from the computation of diluted net income (loss) per share if their effect is antidilutive.

Segments

Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company’s chief operating decision maker reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment.

Information about the Company’s total revenues, based on shipment destination or services location, is presented in the following table:

	Three Months Ended
	March 31,
	2017		2016
	(In thousands)
Revenue:
U.S.	$	9,130	$	11,413
International		13,872		21,408
Total	$	23,002	$	32,821

Warranty Costs

The Company provides warranties for its products and records the estimated cost within cost of sales in the period that the related revenue is recorded. The Company’s standard warranty period extends to one year from the date of shipment. The standard warranties provide that the Company’s products will be free from defects in material and workmanship, and will, under normal use, conform to the specifications for the product.

The Company’s products may be utilized in systems that may involve new technical demands and new configurations. As such, the Company regularly reviews and assesses whether warranty reserves shall be recorded in the period the related revenue is recorded. For an initial shipment of product in a system with new technical demands or configurations and where the Company is unsure of meeting the customer’s specifications, the Company will defer the recognition of product revenue and related costs until written customer acceptance is obtained.

During the three months ended March 31, 2017, the Company recorded warranty expense of $0.9 million. This specific warranty charge was related to a product claim for a specific product application issue.

Recently Issued Accounting Standards

In March 2016, the FASB issued ASU 2016-09. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in ASU 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company has adopted this standard effective January 1, 2017. The provision of ASU 2016-09 related to the timing of accounting for the forfeitures of share based awards was adopted using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of January 1, 2017 of $0.3 million. The other provisions of ASU 2016-09 have been adopted prospectively.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). FASB ASU 2016-02 changes the accounting for leases and includes a requirement to record all leases on the consolidated balance sheets as assets and liabilities. This update is effective for fiscal years beginning after December 15, 2018. Early application is permitted. The Company has not yet selected a transition method and is evaluating the effect the updated standard will have on its consolidated financial statements and related disclosures.

In August 2015, the FASB issued a deferral of ASU 2014-09, Revenue from Contracts with Customers. The standard will eliminate the transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. As a result of the deferral, public entities are required to apply the revenue recognition standard for the annual reporting period beginning on or after December 15, 2017, including interim periods within that annual reporting period. Early application is permitted only as of annual and interim periods in fiscal years beginning after December 15, 2016. The Company expects to adopt the modified retrospective method and is evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures.

In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), which, for entities that do not measure inventory using the last-in, first-out (LIFO) or retail inventory method, changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. The ASU also eliminates the requirement for these entities to consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. Public entities are required to apply the standards for fiscal years beginning after December 15, 2016, including interim periods within those fiscal periods. The Company adopted this standard effective January 1, 2017. There was no material impact on the Company’s consolidated financial statements and disclosures.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). This amendment addresses eight classification issues related to the statement of cash flows. For public business entities, the amendments in ASU 2016-15 are effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. The Company has not yet selected a transition method and is evaluating the effect the updated standard will have on its consolidated financial statements and related disclosures.

(3) Inventories

Inventories consist of the following:

	March 31,		December 31,
	2017		2016
	(In thousands)
Raw materials	$	3,556	$	3,511
Finished goods		11,576		9,357
Total	$	15,132	$	12,868

(4) Property, Plant and Equipment, Net

Property, plant and equipment consist of the following:

	March 31,			December 31,			Useful
	2017			2016			life
	(In thousands)
Construction in progress	$	11,216		$	11,139			—
Buildings		23,929			23,901		30 years
Machinery and equipment		114,370			113,659		3-10 years
Computer equipment and software		7,817			7,679		3 years
Total		157,332			156,378
Accumulated depreciation		(74,613	)		(71,984	)
Property, plant and equipment, net	$	82,719		$	84,394

Depreciation expense was $2.7 million and $2.4 million for the three months ended March 31, 2017 and 2016, respectively.

Construction in progress totaled $11.2 million and $11.1 million at March 31, 2017 and December 31, 2016, respectively, which included engineering designs and other pre-construction costs for the planned manufacturing facility in Statesboro, Georgia of $7.2 million at March 31, 2017 and December 31, 2016.

(5) Accrued Expenses

Accrued expenses consist of the following:

	March 31,		December 31,
	2017		2016
	(In thousands)
Employee compensation	$	2,661	$	2,796
Other accrued expenses		1,451		1,191
Total	$	4,112	$	3,987

(6) Commitments and Contingencies

Customer Supply Agreement

During 2016, the Company entered into a supply agreement and a side agreement (together, the Supply Agreement) and a joint development agreement (the JDA) with BASF SE (BASF). Pursuant to the Supply Agreement, the Company will sell exclusively to BASF the Company’s Spaceloft ^® A2 product at annual volumes to be specified by BASF, subject to certain volume limits. The Supply Agreement will terminate on December 31, 2027. Upon expiration of the Supply Agreement, the Company will be subject to a post-termination supply commitment for an additional two years. The JDA is designed to facilitate the collaboration between the parties on the development and commercialization of new products.

In addition, under the terms of the Supply Agreement, BASF will make a non-interest bearing prepayment to the Company in the aggregate amount of $22 million during the construction of the Company’s planned manufacturing facility in Statesboro, Georgia (Plant Two), subject to the Company’s prior satisfaction of certain preconditions, including securing a debt commitment from a third party lender for at least $30 million. BASF is obligated to pay the prepayment to the Company in eight equal consecutive quarterly installments commencing on the first day of the calendar quarter following the date on which the preconditions are met. Once

commenced, BASF’s obligation to make such quarterly payments shall be subject to postponement in the event of delays of three months or more in the projected date of completion of Plant Two by a commensurate number of months.

After October 1, 2018, the Company will, at BASF’s instruction, credit up to 25.3% of any amounts invoiced by the Company for Spaceloft ^® A2 product sold to BASF against the prepayment balance. However, BASF has no obligation to purchase products under the Supply Agreement. If any of the prepayment remains uncredited against amounts invoiced by the Company as of September 30, 2023, BASF may request that the Company repay the uncredited amount to BASF in four equal quarterly installments beginning on December 31, 2023. The repayment obligation will be secured by a security interest in real estate, plant and equipment at the Company’s Rhode Island and Georgia manufacturing facilities.

As of March 31, 2017, the Company anticipates that the impact of constrained capital investment and low activity levels in the global energy markets will continue through 2017. With this view of the market, the Company has elected to temporarily delay the board approved Plant Two project and its related financing to better align the capacity expansion with the Company’s assessment of demand for the 2018 to 2020 period. As a result, the Company has yet to fulfill the prepayment preconditions and commencement of the quarterly prepayments from BASF will be delayed until the preconditions are satisfied.

Revolving Line of Credit

The Company entered into an Amended and Restated Loan and Security Agreement with Silicon Valley Bank (Loan Agreement), on August 31, 2014, which has been subsequently amended from time to time. On January 27, 2017, the Loan Agreement was amended to extend the maturity date of the revolving credit facility to January 28, 2018. Under the Loan Agreement, the Company may borrow up to $20 million subject to compliance with certain covenants and borrowing base limitations. At the Company’s election, the interest rate applicable to borrowings may be based on the prime rate or LIBOR. Prime rate-based rates vary from prime rate plus 0.75% per annum to prime rate plus 1.75% per annum, while LIBOR-based rates vary from LIBOR plus 3.75% per annum to LIBOR plus 4.25% per annum. In addition, the Company is required to pay a monthly unused line fee of 0.5% per annum of the average unused portion of the facility. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in all assets of the Company, including those at the East Providence facility, except for certain exclusions.

At March 31, 2017 and December 31, 2016, the Company had no amounts drawn on the revolving credit facility. Under the Loan Agreement, the Company is required to comply with both non-financial and financial covenants, including minimum Adjusted EBITDA and minimum Adjusted Quick Ratio, as defined. At March 31, 2017, the Company was in compliance with all such financial covenants.

The Company has been required to provide its landlord for its Northborough, Massachusetts facility with letters of credit securing certain obligations. As of January 31, 2017, these obligations were released by the landlord. In addition, the Company has been required to provide certain customers with letters of credit securing obligations under commercial contracts. The Company had outstanding letters of credit backed by the revolving credit facility of $2.4 million and $2.7 million at March 31, 2017 and December 31, 2016, respectively, which reduce the funds otherwise available to the Company under the facility. Based on the available borrowing base, the effective amount available to the Company under the revolving credit facility at March 31, 2017 was $9.7 million after consideration of the $2.4 million of outstanding letters of credit.

Litigation

The Company is, from time to time, a party to litigation that arises in the normal course of its business operations. See Part II, Item 1 (“Legal Proceedings”) of this Quarterly Report on Form 10-Q for a description of certain of the Company’s current legal proceedings. The Company is not presently a party to any litigation for which it believes a loss is probable requiring an amount to be accrued or a possible loss contingency requiring disclosure.

(7) Deferred Rent

For leases that contain fixed increases in the minimum annual lease payment during the original term of the lease, the Company recognizes rental expense on a straight-line basis over the lease term, and records the difference between rent expense and the amount currently payable as deferred rent.

deferred rent liability on the consolidated balance sheet. The deferred rent liability is being amortized as a reduction to rent expense over the life of the lease.

Cash flows from the landlord for the reimbursement of improvements have been reported within cash from operating activities, while cash flows remitted for the acquisition of leasehold improvements are classified within investing activity cash flows. As of March 31, 2017, deferred rent included $0.8 million in deferred lease incentives and $0.5 million of straight-line rental obligations.

Deferred rent consists of the following:

	March 31,			December 31,
	2017			2016
	(In thousands)
Deferred rent	$	1,251		$	1,125
Current maturities of deferred rent		(169	)		(154	)
Deferred rent, less current maturities	$	1,082		$	971

(8) Net Loss Per Share

The computation of basic and diluted net loss per share consists of the following:

	Three Months Ended
	March 31,
	2017			2016
	(In thousands, except share and per share data)
Numerator:
Net loss	$	(9,078	)	$	(1,797	)
Denominator:
Weighted average shares outstanding, basic and diluted		23,257,541			23,063,471
Net loss per share, basic and diluted	$	(0.39	)	$	(0.08	)

Potentially dilutive common shares that were excluded from the computation of diluted net loss per share because they were anti-dilutive consist of the following:

	Three Months Ended
	March 31,
	2017		2016
Common stock options		2,382,710		1,952,879
Restricted common stock units		954,928		759,510
Common stock warrants		115		131
Restricted common stock awards		153,277		132,130
Total		3,491,030		2,844,650

In the table above, anti-dilutive shares consist of those common stock equivalents that have (i) an exercise price above the average stock price for the period or (ii) related average unrecognized stock compensation expense sufficient to buy back the entire amount of shares. The Company excludes the shares issued in connection with restricted stock awards from the calculation of basic weighted average common shares outstanding until the restrictions lapse.

(9) Income Taxes

The Company incurred net operating losses and recorded a full valuation allowance against net deferred tax assets for all periods presented. Accordingly, the Company has not recorded a provision for federal or state income taxes.

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following information should be read in conjunction with the unaudited financial information and the notes thereto included in this Quarterly Report on Form 10-Q and the audited financial information and the notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2016, filed with the Securities and Exchange Commission on March 2, 2017, which we refer to as the Annual Report.

Certain matters discussed in this Quarterly Report on Form 10-Q may be deemed to be forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. In this Quarterly Report on Form 10-Q, words such as “may,” “will,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.

Our actual results and the timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report, they may not be predictive of results or developments in future periods.

The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, Item 1A of this Quarterly Report on Form 10-Q, and under “Risk Factors” in Item 1A of the Annual Report.

We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

You should read the following discussion and analysis of financial condition and results of operations together with Part I Item 1 “Financial Statements,” which includes our financial statements and related notes, elsewhere in this Quarterly Report on Form 10-Q.

Overview

We design, develop and manufacture innovative, high-performance aerogel insulation used primarily in the energy infrastructure and building materials markets. We believe our aerogel blankets deliver the best thermal performance of any widely used insulation product available on the market today and provide a combination of performance attributes unmatched by traditional insulation materials. Our end-use customers select our products where thermal performance is critical and to save money, reduce energy use, preserve operating assets and protect workers.

Our insulation is used by oil producers and the owners and operators of refineries, petrochemical plants, LNG facilities, power generating assets and other energy infrastructure. Our Pyrogel and Cryogel product lines have undergone rigorous technical validation by industry leading end-users and achieved significant market adoption. We also derive product revenue from the building materials and other end markets. Customers in these markets use our products for applications as diverse as wall systems, military and commercial aircraft, trains, buses, appliances, apparel, footwear and outdoor gear.

We generate product revenue through the sale of our line of aerogel blankets. We market and sell our products primarily through a sales force based in North America, Europe and Asia. The efforts of our sales force are supported by a small number of sales consultants with extensive knowledge of a particular market or region. Our sales force is responsible for establishing and maintaining customer and partner relationships, delivering highly technical information and ensuring high-quality customer service.

Our salespeople work directly with end-use customers and engineering firms to promote the qualification, specification and acceptance of our products. We also rely on an existing and well-established channel of qualified insulation distributors and contractors in more than 30 countries around the world that ensures rapid delivery of our products and strong end-user support. Our salespeople also work to educate insulation contractors about the technical and operating cost advantages of our aerogel blankets.

We also perform research services under contracts with various agencies of the U.S. government, including the Department of Defense and the Department of Energy, and other institutions. Research performed under contract with government agencies and other institutions enables us to develop and leverage technologies into broader commercial applications.

We manufacture our products using our proprietary process and technology at our facility in East Providence, Rhode Island. We completed the construction and start-up of a third production line in the East Providence facility during the first quarter of 2015 with a total construction cost of $31.8 million. The third production line increased our annual nameplate capacity to approximately 50 million square feet of aerogel blankets. During the first quarter of 2016, we announced the planned construction of a second manufacturing facility in Statesboro, Georgia supported by a package of incentives from the State of Georgia and local governmental authorities. During the fourth quarter of 2016, we elected to delay construction of this facility to better align the capacity expansion with our assessment of demand for the 2018 to 2020 time period.

During 2016, we entered into a strategic partnership with BASF SE to develop and commercialize products for the building materials and other markets. The strategic partnership included a supply agreement governing the sale of our Spaceloft A2 product to BASF and a joint development agreement targeting innovative products and technologies. Subject to certain preconditions, BASF also agreed to make a series of prepayments to us in the aggregate of $22 million during the construction of our planned manufacturing facility in Statesboro, Georgia. The prepayments will be either credited against amounts invoiced to BASF for Spaceloft A2 or repaid by us to BASF after December 31, 2023. As a result of our decision to delay construction of the Statesboro facility, we have yet to fulfill the preconditions, and commencement of the prepayments from BASF will be delayed until the preconditions are satisfied.

Our revenue for the three months ended March 31, 2017 was $23.0 million, which represented a decrease of $9.8 million from the three months ended March 31, 2016. Net loss for the three months ended March 31, 2017 was $9.1 million and net loss per diluted share was $0.39. Net loss for the three months ended March 31, 2016 was $1.8 million and net loss per diluted share was $0.08.

Key Metrics and Non-GAAP Financial Measures

We regularly review a number of metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate financial projections and make strategic decisions.

Square Foot Operating Metric

We price our product and measure our product shipments in square feet. We estimate our annual nameplate capacity was approximately 50 million square feet of aerogel blankets at March 31, 2017. We believe the square foot operating metric allows us and our investors to measure our manufacturing capacity and product shipments on a uniform and consistent basis. The following chart sets forth product shipments associated with recognized revenue in square feet for the periods presented:

		Three Months Ended
		March 31,
		2017		2016
	(In thousands)
Product shipments in square feet			8,273		11,846

Adjusted EBITDA

We use Adjusted EBITDA, a non-GAAP financial measure, as a means to assess our operating performance. We define Adjusted EBITDA as net income (loss) before interest expense, taxes, depreciation, amortization, stock-based compensation expense and other items, which occur from time to time, that we do not believe are indicative of our core operating performance. Adjusted EBITDA is a supplemental measure of our performance that is not presented in accordance with U.S. GAAP. Adjusted EBITDA should not be considered as an alternative to net income (loss) or any other measure of financial performance calculated and presented in accordance with U.S. GAAP. In addition, our definition and presentation of Adjusted EBITDA may not be comparable to similarly titled measures presented by other companies.

We use Adjusted EBITDA:

•

as a measure of operating performance because it does not include the impact of items that we do not consider indicative of our core operating performance;

•

for planning purposes, including the preparation of our annual operating budget,

•

to allocate resources to enhance the financial performance of our business; and

•

as a performance measure under our bonus plan.

We also believe that the presentation of Adjusted EBITDA provides useful information to investors with respect to our results of operations and in assessing the performance and value of our business. Various measures of EBITDA are widely used by investors to measure a company’s operating performance without regard to items that can vary substantially from company to company depending upon financing and accounting methods, book values of assets, capital structures and the methods by which assets were acquired.

Although measures similar to Adjusted EBITDA are frequently used by investors and securities analysts in their evaluation of companies, we understand that Adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for net income (loss), income (loss) from operations, net cash provided by (used in) operating activities or an analysis of our results of operations as reported under U.S. GAAP. Some of these limitations are:

•

Adjusted EBITDA does not reflect our historical cash expenditures or future requirements for capital expenditures or other contractual commitments;

•

Adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs;

•

Adjusted EBITDA does not reflect stock-based compensation expense;

•

Adjusted EBITDA does not reflect our income tax expense or cash requirements to pay our income taxes;

•

Adjusted EBITDA does not reflect our interest expense, or the cash requirements necessary to service interest or principal payments on our debt;

•

Although depreciation, amortization and impairment charges are non-cash charges, the assets being depreciated, amortized or impaired will often have to be replaced in the future, and Adjusted EBITDA does not reflect any cash requirements for these replacements; and

•

Other companies in our industry may calculate EBITDA or Adjusted EBITDA differently than we do, limiting their usefulness as a comparative measure.

Because of these limitations, our Adjusted EBITDA should not be considered as a measure of discretionary cash available to us to reinvest in the growth of our business or as a measure of cash available for us to meet our obligations.

To properly and prudently evaluate our business, we encourage you to review the U.S. GAAP financial statements included elsewhere in this Quarterly Report on Form 10-Q, and not to rely on any single financial measure to evaluate our business.

The following table presents a reconciliation of net loss, the most directly comparable U.S. GAAP measure, to Adjusted EBITDA for the periods presented:

	Three Months Ended
	March 31,
	2017			2016
	(In thousands)
Net loss	$	(9,078	)	$	(1,797	)
Depreciation and amortization		2,676			2,410
Stock-based compensation ⁽¹⁾		1,244			1,370
Interest expense		26			39
Adjusted EBITDA	$	(5,132	)	$	2,022

₍₁₎ Represents non-cash stock-based compensation related to vesting and modifications of stock option grants, vesting of restricted stock units and vesting of restricted common stock.

Our financial performance, including such measures as net income (loss), earnings per share and Adjusted EBITDA, are affected by a number of factors including volume and mix of aerogel products sold, average selling prices, our material and manufacturing costs, the costs associated with and timing of expansions and start-up of additional production capacity, and the amount and timing of operating expenses, including patent enforcement costs. As we build out our manufacturing capacity in the longer term, we expect increased manufacturing expenses will periodically have a negative impact on net income (loss), earnings per share and Adjusted EBITDA, but will set the framework for improved performance in the long term. Accordingly, we expect that our net income (loss), earnings per share and Adjusted EBITDA will vary from period to period, in particular as and when we expand our manufacturing capacity.

As a result of the conclusion of a multiyear petrochemical project with a major Asian energy company, which comprised 25% of our product revenue during 2016, in combination with the impact of constrained capital investment and low activity levels in the global energy infrastructure market, we expect a decrease in revenue and an associated increase in net loss and loss per share and a decrease in Adjusted EBITDA during the year ending December 31, 2017 versus the comparable period in 2016. Given fixed cost structures and lag times for implementing reductions of certain variable costs, the percentage increase in net loss and loss per share and decrease in Adjusted EBITDA could be significantly greater than any percentage decrease in revenue.

Components of Our Results of Operations

Revenue

We recognize product revenue from the sale of our line of aerogel products and research services revenue from the provision of services under contracts with various agencies of the U.S. government and other institutions. Product revenue is recognized upon transfer of title and risk of loss, which is upon shipment or delivery.

We record deferred revenue for product sales when (i) we have delivered products but other revenue recognition criteria have not been satisfied or (ii) payments have been received in advance of products being delivered.

Cost of Revenue

Cost of revenue for our product revenue consists primarily of materials and manufacturing expense, including labor, utilities, maintenance expense and depreciation on manufacturing assets. Cost of product revenue is recorded when the related product revenue is recognized. Cost of product revenue also includes stock-based compensation of manufacturing employees and shipping costs.

Material costs as a percentage of product revenue vary from product to product due to differences in average selling prices, material requirements, blanket thicknesses and manufacturing yields. In addition, we provide warranties for our products and record the estimated cost within cost of sales in the period that the related revenue is recorded. As a result, material costs as a percentage of revenue will vary from period to period due to changes in the mix of aerogel products sold or the estimated cost of warranties. However, in the longer term, we expect material costs in the aggregate to decline as a percentage of revenue as we seek to achieve higher selling prices, material sourcing improvements, quality improvements and manufacturing yield enhancements for our aerogel products.

Manufacturing expense is also a significant component of cost of revenue. As we increase manufacturing capacity through our planned construction and operation of a second manufacturing facility and, over time, potentially expand the production lines at the second facility, we expect manufacturing expense as a percentage of product revenue will increase following each expansion but will decrease in the long-term with increased revenues supported by the effect of completed capacity expansions.

Cost of revenue for our research services revenue consists of direct labor costs of research personnel engaged in the contract research, third-party consulting expense, and associated direct material costs. This cost of revenue also includes overhead expenses associated with project resources, development tools and supplies. Cost of revenue for our research services revenue is recorded when the related research services revenue is recognized.

Gross Profit

Our gross profit as a percentage of revenue is affected by a number of factors, including the volume of aerogel products produced and sold, the mix of aerogel products sold, average selling prices, our material and manufacturing costs, realized capacity utilization and the costs associated with expansions and start-up of production capacity. Accordingly, we expect our gross profit in absolute dollars and as a percentage of revenue to vary significantly from period to period. As we build out our manufacturing capacity, we expect increased manufacturing expenses will periodically have a significant negative impact on gross profit in the periods following any such expansion.

As a result of the conclusion of the multiyear petrochemical project with a major Asian energy company, which comprised 25% of our product revenue during 2016, in combination with the impact of constrained capital investment and low activity levels in the global energy infrastructure market, we expect a decrease in revenue and an associated decrease in gross profit and gross profit as a percentage of revenue during 2017. Given fixed cost structures and lag times for implementing reductions of certain variable costs, the percentage decrease in gross profit could be significantly greater than any percentage decrease in revenue. However, in the longer term, we expect gross profit to improve as a percentage of revenue in the longer term due to expected increases in manufacturing productivity and production volumes, supported by expected capacity expansions, improvements in manufacturing yields and realization of material purchasing efficiencies.

Operating Expenses

Operating expenses consist of research and development, sales and marketing, and general and administrative expenses. Operating expenses include personnel costs, legal fees, professional fees, service fees, insurance premiums, travel expense, facilities related costs and other costs and fees. The largest component of our operating expenses is personnel costs, consisting of salaries, benefits, incentive compensation and stock-based compensation. In any particular period, the timing and extent of personnel additions or reductions, legal activities, including patent enforcement actions, marketing programs, research efforts and a range of similar activities or actions could materially affect our operating expenses, both in absolute dollars and as a percentage of revenue.

Research and Development Expenses

Research and development expenses consist primarily of expenses for personnel engaged in the development of next generation aerogel compositions, form factors and manufacturing technologies. These expenses also include testing services, prototype expenses, consulting services, equipment depreciation, facilities costs and related overhead. We expense research and development costs as incurred. We expect to continue to devote substantial resources to the development of new aerogel technology. We believe that these investments are necessary to maintain and improve our competitive position. We expect to continue to invest in research and engineering personnel and the infrastructure required in support of their efforts. While we expect that our research and development expenses will increase in absolute dollars but decrease as a percentage of revenue in the longer term, we expect such expenses will increase as a percentage of revenue during 2017.

Sales and Marketing Expenses

Sales and marketing expenses consist primarily of personnel costs, incentive compensation, marketing programs, travel and related costs, consulting expenses and facilities related costs. We plan to expand our sales force and sales consultants globally to drive anticipated growth in customers and demand for our products. While we expect that sales and marketing expenses will increase in absolute dollars but decrease as a percentage of revenue in the longer-term, we expect such expenses will increase as a percentage of revenue during 2017.

General and Administrative Expenses

General and administrative expenses consist primarily of personnel costs, legal expenses, consulting and professional services, audit and tax consulting costs, and expenses for our executive, finance, human resources and information technology organizations. General and administrative expenses have increased as we have incurred additional costs related to operating as a publicly-traded company, which include costs of compliance with securities, corporate governance and related laws and regulations, investor relations expenses, increased insurance premiums, including director and officer insurance, and increased audit and legal fees. In addition, we expect our general and administrative expenses to increase as we add general and administrative personnel to support the anticipated growth of our business and continued expansion of our manufacturing operations. We also expect that the patent enforcement actions, described in more detail under “Legal Proceedings” in Part II, Item 1 of this Quarterly Report on Form 10-Q, will result in a near-term increase in legal expense and, if such litigation is protracted, could result in significant additional legal expense over the medium to long-term. During 2017, we expect general and administrative expense will increase both in absolute dollars and as a percentage of revenue. In the longer term, we expect that general and administrative expenses will decrease both in absolute dollars and as a percentage of revenue.

Other Expense, Net

For the three months ended March 31, 2017 and 2016, other expense, net consisted primarily of fees related to our revolving credit facility.

Provision for Income Taxes

We have incurred net losses since inception and have not recorded benefit provisions for U.S. federal income taxes or state income taxes since the tax benefits of our net losses have been offset by valuation allowances due to the uncertainty associated with the utilization of net operating loss carryforwards.

Results of Operations

Three months ended March 31, 2017 compared to the three months ended March 31, 2016

The following tables set forth a comparison of the components of our results of operations for the periods presented:

Revenue

	Three Months Ended March 31,
	2017					2016					Change
			Percentage					Percentage
	Amount		of Revenue			Amount		of Revenue			Amount			Percentage
	($ in thousands)
Revenue:
Product	$	22,326		97	%	$	32,286		98	%	$	(9,960	)		(31	)%
Research services		676		3	%		535		2	%		141			26	%
Total revenue	$	23,002		100	%	$	32,821		100	%	$	(9,819	)		(30	)%

The following chart sets forth product shipments in square feet for the periods presented:

	Three Months Ended March 31,				Change
	2017		2016		Amount			Percentage
Product shipments in square feet (in thousands)		8,273		11,846		(3,573	)		(30	)%

Total revenue decreased $9.8 million, or 30%, to $23.0 million for the three months ended March 31, 2017 from $32.8 million in the comparable period in 2016 primarily as a result of a decrease in product revenue.

Product revenue decreased by $10.0 million, or 31%, to $22.3 million for the three months ended March 31, 2017 from $32.3 million in the comparable period in 2016. This decrease was principally the result of a decrease in sales to a major Asian energy company associated with the conclusion of a multiyear petrochemical project, a decline in project work in the subsea market, and a broad based decline in revenue in the global downstream market.

Product revenue for the three months ended March 31, 2017 included $3.7 million to a North American distributor, $3.4 million to an Asian distributor and $2.6 million to a North American manufacturer. Product revenue for the three months ended March 31, 2016 included $6.7 million to a major Asian energy company, $4.7 million to a North American distributor and $3.6 million to an Asian distributor.

The average selling price per square foot of our products decreased by $0.03, or 1%, to $2.70 per square foot for the three months ended March 31, 2017 from $2.73 per square foot for the three months ended March 31, 2016. The decrease in average selling price reflected a year-over-year decline in the mix of high-priced subsea products, offset, in large part, by a decrease in the mix of products sold to the major Asian energy company with lower, project-based pricing. This decrease in average selling price had the effect of decreasing product revenue by $0.2 million for the three months ended March 31, 2017 from the comparable period in 2016.

In volume terms, product shipments decreased by 3.6 million square feet, or 30%, to 8.3 million square feet of aerogel products for the three months ended March 31, 2017, as compared to 11.8 million square feet for the three months ended March 31, 2016. The decrease in product volume had the effect of decreasing product revenue by $9.8 million for the three months ended March 31, 2017 from the comparable period in 2016.

Research services revenue increased $0.2 million, or 26%, to $0.7 million for the three months ended March 31, 2017 from $0.5 million in the comparable period in 2016. The increase was primarily due to the timing and amount of funding available under existing research contracts during the three months ended March 31, 2017 from the comparable period in 2016.

Product revenue was 97% of total revenue for the three months ended March 31, 2017 and 98% for the three months ended March 31, 2016. Research services revenue was 3% of total revenue for the three months ended March 31, 2017 and 2% of total revenue for the three months ended March 31, 2016.

Cost of Revenue

	Three Months Ended March 31,
	2017								2016								Change
			Percentage of Related			Percentage of Total					Percentage of Related			Percentage of Total
	Amount		Revenue			Revenue			Amount		Revenue			Revenue			Amount			Percentage
	($ in thousands)
Cost of revenue:
Product	$	20,470		92	%		89	%	$	25,992		81	%		79	%	$	(5,522	)		(21	)%
Research services		311		46	%		1	%		302		56	%		1	%		9			3	%
Total cost of revenue	$	20,781		90	%		90	%	$	26,294		80	%		80	%	$	(5,513	)		(21	)%

Total cost of revenue decreased $5.5 million, or 21%, to $20.8 million for the three months ended March 31, 2017 from $26.3 million in the comparable period in 2016. The decrease in total cost of revenue was the result of a decrease in product cost of revenue.

Product cost of revenue decreased $5.5 million, or 21%, to $20.5 million for the three months ended March 31, 2017 from $26.0 million in the comparable period in 2016. The $5.5 million decrease was the result of a $4.9 million or 34% decrease in material costs and a $0.6 million decrease in manufacturing expense year over year. The decrease in material costs was principally driven by the 31% decrease in product revenue, and, to a lesser extent, a favorable mix of products sold, offset, in part, by an increase in warranty expense of $0.9 million. The decrease in manufacturing expense was the result of decreases in utilities expense of $0.5 million and compensation expense of $0.2 million, offset, in part, by an increase in depreciation expense of $0.1 million.

Product cost of revenue as a percentage of product revenue increased to 92% during the three months ended March 31, 2017 from 81% during the three months ended March 31, 2016 primarily due an increase in manufacturing expense as a percentage of product cost of revenue for the three months ended March 31, 2017 from the comparable period in 2016. This increase was the result of the high proportion of fixed manufacturing expenses that remained essentially unchanged despite the 31% decrease in product revenue for the three months ended March 31, 2017 versus the comparable period in 2016.

Research services cost of revenue was $0.3 million for the three months ended March 31, 2017 and 2016. Cost of research service revenue as a percentage of research services revenue decreased to 46% during the three months ended March 31, 2017 from 56% in the comparable period in 2016 due to the higher mix of internal labor in 2017 versus outside services utilized to support the contracted research.

Gross Profit

	Three Months Ended March 31,
	2017					2016					Change
			Percentage					Percentage
	Amount		of Revenue			Amount		of Revenue			Amount			Percentage
	($ in thousands)
Gross profit	$	2,221		10	%	$	6,527		20	%	$	(4,306	)		(66	)%

Gross profit decreased $4.3 million, or 66%, to $2.2 million for the three months ended March 31, 2017 from $6.5 million in the comparable period in 2016. The decrease in gross profit was the result of the $9.8 million decrease in total revenue offset, in part, by the $5.5 million decrease in total cost of sales. The decrease in revenue was principally associated with the impact of constrained capital investment and low activity levels in the global energy infrastructure market. The decrease in total cost of sales was driven by reduced material costs and, to a lesser extent, decreased manufacturing expenses associated with the 31% decline in product revenue.

Gross profit as a percentage of total revenue decreased to 10% of total revenue for the three months ended March 31, 2017 from 20% in the comparable period in 2016. In 2017, we expect gross profit as a percentage of total revenue will decrease versus 2016. The expected decrease in gross profit reflects our expectation that, given the fixed cost levels in our manufacturing facility, the expected percentage reduction in cost of total revenue will not fully offset the expected percentage reduction in total revenue in 2017.

Research and Development Expenses

	Three Months Ended March 31,
	2017					2016					Change
			Percentage					Percentage
	Amount		of Revenue			Amount		of Revenue			Amount		Percentage
	($ in thousands)
Research and development expenses	$	1,576		7	%	$	1,310		4	%	$	266		20	%

Research and development expenses increased $0.3 million, or 20%, to $1.6 million for the three months ended March 31, 2017 from $1.3 million in the comparable period in 2016. The $0.3 million increase was primarily due to an increase of $0.2 million in compensation related expenses and a $0.1 million increase in depreciation expense.

Research and development expenses as a percentage of total revenue increased to 7% for the three months ended March 31, 2017 as compared to 4% in the comparable period in 2016 primarily due to the decline in total revenue for the three months ended March 31, 2017.

We expect that our research and development expenses during 2017 will increase from 2016 expense levels in support of new product development, improved manufacturing technology and the costs associated with the operation of our newly constructed full scale pilot line. Due to the expected growth in research and development expenses and the projected decline in total revenue, we expect research and development expenses as a percentage of total revenue to increase in 2017. In the long term, we expect to continue to increase investment in research, development and engineering personnel, projects and infrastructure in support of efforts to develop new products, technologies and markets. However, we expect that research and development expenses will decline as a percentage of total revenue in the long-term due to projected growth in product revenue.

Sales and Marketing Expenses

	Three Months Ended March 31,
	2017					2016					Change
			Percentage					Percentage
	Amount		of Revenue			Amount		of Revenue			Amount		Percentage
	($ in thousands)
Sales and marketing expenses	$	3,110		14	%	$	3,062		9	%	$	48		2	%

Sales and marketing expenses remained flat at $3.1 million for the three months ended March 31, 2017 from the comparable period in 2016. Increases in compensation related costs of $0.1 million were offset by reductions in general marketing expenses of $0.1 million.

Sales and marketing expenses as a percentage of total revenue increased to 14% for the three months ended March 31, 2017 from 9% in the comparable period in 2016 due principally to the decline in total revenue during the three months ended March 31, 2017.

We expect sales and marketing expenses to increase modestly during 2017 in line with a planned increase in sales personnel and marketing efforts. Due to the expected growth in sales and marketing expenses and the projected decline in total revenue, we expect sales and marketing expenses as a percentage of total revenue to increase in 2017. In the long term, we expect that sales and marketing expenses will increase in absolute dollars as we continue to increase sales personnel and marketing efforts in support of expected growth in demand for our products. However, we expect that sales and marketing expenses will decrease as a percentage of total revenue in the long-term due to projected growth in product revenue.

General and Administrative Expenses

	Three Months Ended March 31,
	2017					2016					Change
			Percentage					Percentage
	Amount		of Revenue			Amount		of Revenue			Amount		Percentage
	($ in thousands)
General and administrative expenses	$	6,587		29	%	$	3,913		12	%	$	2,674		68	%

General and administrative expenses increased $2.7 million, or 68% to $6.6 million during the three months ended March 31, 2017 from $3.9 million in the comparable period in 2016. The $2.7 million increase was primarily the result of increases in patent enforcement costs of $2.5 million, payroll and related costs of $0.2 million, and legal and professional fees of $0.1 million, offset, in part, by a decrease in stock-based compensation expense of $0.1 million.

General and administrative expenses as a percentage of total revenue increased to 29% for the three months ended March 31, 2017 from 12% in the comparable period in 2016. This increase was due to the combined effect of the increase in patent enforcement costs and the decline in total revenue during the three months ended March 31, 2017.

We expect general and administrative expenses to increase during 2017 as we expect to pay incentive based compensation related to 2017 performance that did not occur in 2016. Due to the expected growth in general and administrative expenses and the projected decline in total revenue, we expect general and administrative expenses as a percentage of total revenue to increase in 2017. We also expect that the patent enforcement actions, described in more detail under “Legal Proceedings” in Part II, Item 1, of this Quarterly Report on Form 10-Q, will result in high levels of legal expense in the near term and, if such actions are protracted, could result in significant additional legal expense over the medium to long term. In the long term, we expect to continue to increase general and administrative personnel and expense levels to support the anticipated growth of our business and continued expansion of our manufacturing operations. As a result, we expect that general and administrative expenses will increase in absolute dollars but decrease as a percentage of revenue due to projected growth in product revenue.

Other Expense, net

	Three Months Ended March 31,
	2017						2016						Change
				Percentage						Percentage
	Amount			of Revenue			Amount			of Revenue			Amount		Percentage
	($ in thousands)
Interest expense, net	$	(26	)		(0	)%	$	(39	)		(0	)%	$	13		(33	)%

Other expense, net of less than $0.1 million during the three months ended March 31, 2017 and 2016 was comprised primarily of costs related to our revolving credit facility.

Liquidity and Capital Resources

Overview

We have experienced significant losses and invested substantial resources since our inception to develop and commercialize our aerogel technology and to build a manufacturing infrastructure capable of supplying aerogel products at the volumes and costs required by our customers. These investments have included research and development and other operating expenses, capital expenditures and investment in working capital balances.

Through 2015, we experienced revenue growth and gained share in our target markets. Despite a decline in revenue in 2016 and an expected decline in revenue in 2017, our financial projections anticipate long-term revenue growth, with increasing levels of gross profit and improved cash flows from operations. However, we expect to incur significant capital expenditures related to the expansion of our manufacturing capacity to support this expected long term growth in demand.

We believe that our existing cash balance and available credit will be sufficient to fund the design and development and a portion of the construction of our second manufacturing facility. We expect to supplement our cash balance and available credit with anticipated cash flows from operations, local government grants, debt financings, customer prepayments and potentially equity financings to provide the capital required to complete the first production line in our second manufacturing facility.

We currently anticipate that constrained capital investment and low activity levels in the global energy markets will continue through 2017. With this view of the market, we elected in late 2016 to temporarily delay the board approved project to construct a second manufacturing facility and its related financing to better align the capacity expansion with our assessment of demand for the 2018 to 2020 period. In addition, we intend to manage capital expenditures and working capital balances during 2017 to maintain the cash resources required to support current operating requirements and our long term capacity plan.

Primary Sources of Liquidity

Our principal sources of liquidity are currently our cash and cash equivalents and our revolving credit facility with Silicon Valley Bank. Cash and cash equivalents consist primarily of cash and money market accounts on deposit with banks. As of March 31, 2017, we had $11.2 million of cash and cash equivalents.

At March 31, 2017, our only debt obligations were less than $0.1 million related to capital lease obligations. At March 31, 2017, we also had $2.4 million of outstanding letters of credit secured by the revolving credit facility with Silicon Valley Bank.

We have maintained the revolving credit facility with Silicon Valley Bank since March 2011, which has been amended from time to time. Under our revolving credit facility, we are permitted to borrow a maximum of $20.0 million, subject to continued covenant compliance and borrowing base requirements. At our election, the interest rate applicable to borrowings under the amended revolving credit facility may be based on the prime rate or LIBOR. Prime rate-based rates vary from prime rate plus 0.75% per annum to prime rate plus 1.75% per annum, while LIBOR-based rates vary from LIBOR plus 3.75% per annum to LIBOR plus 4.25% per annum. In addition, we are required to pay a monthly unused revolving line facility fee of 0.5% per annum of the average unused portion of the revolving credit facility. The revolving credit facility matures on January 28, 2018.

Due to the borrowing base limitations of the revolving credit facility, the effective amount available to us under the facility at March 31, 2017 was $9.7 million after giving effect to the $2.4 million of letters of credit outstanding. As of March 31, 2017, we had no outstanding balances drawn on the revolving credit facility.

Analysis of Cash Flow

Net Cash Used in Operating Activities

During the three months ended March 31, 2017, we used $4.4 million in net cash in operating activities, as compared to the use of $0.2 million in net cash during the comparable period in 2016, an increase in the use of cash of $4.2 million. This increase in use of cash was the result of the increase in net loss adjusted for non-cash items of $7.2 million, offset, in part, by an increase in cash provided by changes in operating assets and liabilities of $2.8 million.

Net Cash Used in Investing Activities

Net cash used in investing activities is primarily related to capital expenditures to support our growth. Net cash used in investing activities for the three months ended March 31, 2017 and 2016 was $2.1 million and $3.1 million, respectively.

Net cash used in investing activities for the three months ended March 31, 2017 included a total of $2.1 million in capital expenditures for machinery and equipment to improve the throughput and efficiency of our East Providence facility. Net cash used in investing activities for the three months ended March 31, 2016 included $3.1 million of capital expenditures for the engineering and design and other pre-construction costs related to our planned manufacturing facility in Statesboro, Georgia, and machinery and equipment to improve the throughput and efficiency of our East Providence facility.

Net Cash Used in Financing Activities

Net cash used in financing activities for the three months ended March 31, 2017 totaled $0.3 million and consisted of $0.3 million for payments made for employee tax withholdings associated with the vesting of restricted stock units and less than $0.1 million for repayments of obligations under capital leases. Net cash used in financing activities for the three months ended March 31, 2016 totaled $0.1 million and included $0.1 million for payments made for employee tax withholdings associated with the vesting of restricted stock units and less than $0.1 million for repayments of obligations under capital leases.

Off Balance Sheet Arrangements

Since our inception, we have not engaged in any off balance sheet activities as defined in Item 303(a)(4) of Regulation S-K.

Contractual Obligations and Commitments

There have been no material changes to our contractual obligations and commitments as reported in our Annual Report on Form 10-K for the year ending December 31, 2016, filed with the SEC on March 2, 2017.

Recent Accounting Pronouncements

Information regarding new accounting pronouncements is included in note 2 to our unaudited consolidated financial statements contained in Item 1 of this Quarterly Report on Form 10-Q.

Critical Accounting Policies and Estimates

Our financial statements are prepared in accordance with U.S. GAAP. The preparation of our financial statements and related disclosures requires us to make estimates, assumptions and judgments that affect the reported amount of assets, liabilities, revenue, costs and expenses and related disclosures. We believe that the estimates, assumptions and judgments involved in these accounting policies have the greatest potential impact on our financial statements and, therefore, we consider these to be our critical accounting policies. Accordingly, we evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions and conditions. See our Annual Report on Form 10-K for the year ended December 31, 2016, filed on March 2, 2017 with the Securities and Exchange Commission, and note 2 to our consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for information about these critical accounting policies, as well as a description of our other significant accounting policies.

Certain Factors That May Affect Future Results of Operations

The Securities and Exchange Commission, or SEC, encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This Quarterly Report on Form 10-Q contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties and other important factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our beliefs in the appropriateness of our assumptions, the accuracy of our estimates regarding expenses, loss contingencies, future revenues, future profits, uses of cash, available credit, capital requirements, and the need for additional financing; the performance of our aerogel blankets; our plans to construct a second manufacturing facility in Statesboro, Georgia; our estimates of annual production capacity; our strategic partnership with BASF and the potential benefits of such a relationship, including the potential for it to create new product and market opportunities; our supply agreement with BASF, our exclusive supply to BASF of its Spaceloft^® A2 product, the potential for future cash advances from BASF under the supply agreement (payment of which are subject to certain conditions) to provide a source of financing for some portion of the cost of the planned construction of our proposed manufacturing plant expected to be located in Statesboro, Georgia, and the potential for BASF to become a significant customer for our products; our joint development agreement with BASF, and the potential for it to support the development of new aerogel products and technologies; our beliefs about the usefulness of the square foot operating metric; our beliefs about the financial metrics that are indicative of our core performance; our beliefs about the usefulness of our presentation of Adjusted EBITDA; our expectations about the effect of manufacturing capacity on financial metrics such as Adjusted EBITDA; our beliefs about the outcome, effects or estimated costs of current or potential litigation or their respective timing, including expected legal expense in connection with the Company’s patent enforcement actions; our expectations about hiring additional personnel; our plans to devote substantial resources to the development of new aerogel technology; our expectations about product mix; our expectations about future material costs and manufacturing expenses as a percentage of revenue; our expectations of future gross profit and the effect of manufacturing expenses, manufacturing capacity and productivity on gross profit; our expectations about our resources and other investments in new technology and related research and development activities and associated expenses; our expectations about short and long term (a) research and development (b) general and administrative and (c) sales and marketing expenses; our expectations of near term revenue declines; our expectations of revenue growth, increased gross profit, and improving cash flows over the long term; our intentions about managing capital expenditures and working capital balances; our expectations about incurring significant capital expenditures in the future; our expectations about the expansion of our workforce and resources and its effect on sales and marketing, general and administrative, and related expenses; our expectations about future product revenue and demand for our products; our expectations about the effect of stock based compensation on various costs and expenses; our expectations about potential sources of future financing; our beliefs about the impact of accounting policies on our financial statements; our beliefs about the effect of interest rates, inflation and foreign currency fluctuations on our results of operations and financial condition; and our beliefs about the expansion of our international operations.

Words such as “may,” “will,” “anticipate,” “estimate,” “expects,” “projects,” “intends,” “plans,” “believes” and words and terms of similar substance used in connection with any discussion of future operating or financial performance, identify forward-looking statements. All forward-looking statements are management’s present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described in the forward-looking statements. These risks include, but are not limited to, those set forth in Part II, Item 1A of this Quarterly Report on Form 10-

Q and under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2016.

In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q might not occur. Stockholders and other readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. All subsequent forward-looking statements attributable to Aspen Aerogels, Inc. or to any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.

Item 3.

Quantitative and Qualitative Disclosures About Market Risk.

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure results primarily from fluctuations in interest rates as well as from inflation. In the normal course of business, we are exposed to market risks, including changes in interest rates which affect our line of credit under our revolving credit facility as well as cash flows. We may also face additional exchange rate risk in the future as we expand our business internationally.

Interest Rate Risk

We are exposed to changes in interest rates in the normal course of our business. At March 31, 2017, we had unrestricted cash and cash equivalents of $11.2 million. These amounts were held for working capital and capital expansion purposes and were invested primarily in deposit and money market accounts at a major financial institution in North America. Due to the short-term nature of these investments, we believe that our exposure to changes in the fair value of our cash as a result of changes in interest rates is not material.

As of March 31, 2017, we have no debt outstanding other than capital lease obligations of approximately $0.1 million with fixed interest rates. At March 31, 2017, we also had $2.4 million of outstanding letters of credit.

Under our revolving credit facility, we are permitted to borrow a maximum of $20.0 million, subject to continued covenant compliance and borrowing base requirements. At our election, the interest rate applicable to borrowings under the revolving credit facility may be based on the prime rate or LIBOR. Prime rate-based rates vary from prime rate plus 0.75% per annum to prime rate plus 1.75% per annum, while LIBOR-based rates vary from LIBOR plus 3.75% per annum to LIBOR plus 4.25% per annum. In addition, we are required to pay a monthly unused revolving line facility fee of 0.5% per annum of the average unused portion of the revolving credit facility. The maturity date of our revolving credit facility is January 28, 2018.

Due to the borrowing base limitations, the effective amount available to us under the revolving credit facility at March 31, 2017 was $9.7 million after giving effect to the $2.4 million of letters of credit outstanding. As of March 31, 2017, we had no outstanding balances drawn on the revolving credit facility.

Inflation Risk

Although we expect that our operating results will be influenced by general economic conditions, we do not believe that inflation has had a material effect on our results of operations during the periods presented in this report. However, our business may be affected by inflation in the future.

Foreign Currency Exchange Risk

We are subject to inherent risks attributed to operating in a global economy. Principally all of our revenue, receivables, purchases and debts are denominated in U.S. dollars.

Item 4.

Controls and Procedures.

(a) Evaluation of Disclosure Controls and Procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities and Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and is accumulated and

communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

As of March 31, 2017, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of March 31, 2017, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(b) Changes in Internal Controls.

During the three months ended March 31, 2017, there were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1.

Legal Proceedings.

On May 5, 2016, we filed a complaint for patent infringement against Nano Tech Co., Ltd. (“Nano”) and Guangdong Alison Hi-Tech., Ltd. (“Alison” and, together with Nano, the “Respondents”) in the United States International Trade Commission (the “ITC”). The ITC complaint alleges that these two China-based companies have engaged and are engaging in unfair trade practices by importing aerogel products in the United States that infringe several of the Company’s patents. In the ITC complaint, we are seeking exclusion orders directing United States Customs and Border Protection to stop the importation of infringing products. On June 2, 2016, the ITC instituted an investigation based on our complaint. The investigation is ongoing with participation from the Respondents through their respective counsel. In addition to Respondents’ contention at the ITC that the patents we have asserted are invalid, Alison has also filed petitions with United States Patent and Trademark Office (“USPTO”) requesting Inter-Partes Review to cancel certain claims in three of the asserted manufacturing process patents and a product patent. As of April 27, 2017, the USPTO has denied Alison’s petitions to institute Inter-Partes Review on three manufacturing process patents and has not yet issued a decision on Alison’s petition to institute Inter-Partes Review of the product patent. Alison has also filed similar requests with the Chinese Patent Office (“SIPO”) seeking to invalidate two of our Chinese manufacturing process patents and two of our Chinese product patents.

On April 11, 2016, we also filed a patent infringement suit at the District Court in Mannheim, Germany against the Respondents and two European distributors asserting their infringement of one of our German patents. We subsequently asserted their infringement of another three patents against Nano and a European distributor of Alison’s products at the Mannheim court. We have since settled with the other European distributor in exchange for a commitment not to procure infringing products and cooperation with our case. The litigation against the other defendants is ongoing. Nano has also initiated a nullity action in German Federal Patent Court against one of our asserted German manufacturing process patents. Alison likewise filed an opposition to one of the asserted patents at the European Patent Office on April 18, 2017.

Due to their nature, it is difficult to predict the outcome or the costs involved in any litigation. Furthermore, the Respondents may have significant resources and interest to litigate and therefore, these litigation matters could be protracted and may ultimately involve significant legal expenses. In addition to the foregoing, we have been and may be from time to time party to other legal proceedings that arise in the ordinary course of business and to other patent enforcement actions to assert our patent rights.

Item 1A.

Risk Factors.

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

(a) Unregistered Sales of Equity Securities. Not applicable.

(b) Use of Proceeds from Initial Public Offering of Common Stock.

We registered shares of our common stock in connection with our initial public offering pursuant to a registration statement on Form S-1 (File No. 333-195523), which was declared effective by the SEC on June 12, 2014, and a registration statement on Form S-1 (File No. 333-196719) filed pursuant to Rule 462(b) of the Securities Act of 1933, as amended, or the Securities Act.

We received aggregate net proceeds from the offering of approximately $74.7 million, after deducting $4.3 million of underwriting discounts and approximately $3.5 million of offering expenses.

As of March 31, 2017, we have used $19.8 million of the net proceeds of the offering to repay all amounts outstanding under our subordinated notes and our revolving credit facility; $31.0 million of the net proceeds of the offering for capital expenditures related to our third production line; $7.2 million of the net proceeds of the offering for our planned manufacturing facility in Statesboro, Georgia; and $5.5 million of the net proceeds of the offering for general corporate purposes. The remainder of the net proceeds is held in a deposit account and money market account with a major financial institution in North America. We have broad discretion in the use of the net proceeds from our initial public offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our stock. There has been no material change in our planned use of the balance of the net proceeds from the offering as described in our final prospectus dated June 12, 2014, filed with the SEC on June 16, 2014.

We did not repurchase any of our equity securities during the quarter ended March 31, 2017.

Item 3.

Defaults Upon Senior Securities.

None.

Item 4.

Mine Safety Disclosures.

Not applicable.

Item 5.

Other Information.

None.

Item 6.

Exhibits.

(a) Exhibits

10.1		Fourth Amendment to the Amended and Restated Loan and Security Agreement, dated January 27, 2017, by and between the Company and Silicon Valley Bank.

31.1		Certification of principal executive officer under Section 302(a) of the Sarbanes-Oxley Act of 2002.

31.2		Certification of principal financial officer under Section 302(a) of the Sarbanes-Oxley Act of 2002.

32		Certifications of the principal executive officer and the principal financial officer under Section 906 of the Sarbanes-Oxley Act of 2002.

101		The following materials from Aspen Aerogels, Inc.’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, formatted in XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets (unaudited) as of March 31, 2017 and December 31, 2016, (ii) the Consolidated Statements of Operations (unaudited) for the three months ended March 31, 2017 and 2016, (iii) the Consolidated Statements of Cash Flows (unaudited) for the three months ended March 31, 2017 and 2016, and (iv) the Notes to Consolidated Financial Statements (unaudited).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	ASPEN AEROGELS, INC.

Date: May 4, 2017	By:	/s/ Donald R. Young
		Donald R. Young
		President and Chief Executive Officer (principal executive officer)

Date: May 4, 2017	By:	/s/ John F. Fairbanks
		John F. Fairbanks
		Vice President, Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer)

EX-10.1 2 aspn-ex101_302.htm EX-10.1 aspn-ex101_302.htm

Exhibit 10.1

FOURTH Amendment

AMENDED AND RESTATED Loan and security agreement

This Fourth Amendment to Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into this 27th day of January, 2017 by and between SILICON VALLEY BANK (“Bank”) and ASPEN AEROGELS, INC., a Delaware corporation (“Borrower”) whose address is 30 Forbes Road, Building B, Northborough, Massachusetts 01532.

Recitals

A.Bank and Borrower have entered into that certain Amended and Restated Loan and Security Agreement dated as of September 3, 2014, as amended by that certain Consent and First Amendment to Amended and Restated Loan and Security Agreement dated as of August 19, 2016, as further amended by that certain Second Amendment to Amended and Restated Loan and Security Agreement dated as of November 23, 2016, and as further amended by that certain Third Amendment to Amended and Restated Loan and Security Agreement dated as of December 29, 2016 (as amended, and as the same may from time to time be further amended, restated, amended and restated, modified and/or supplemented, the “Loan Agreement”).

B.Bank has extended credit to Borrower for the purposes permitted in the Loan Agreement.

C.Borrower has requested that Bank amend the Loan Agreement to (i) extend the maturity date, and (ii) make certain other revisions to the Loan Agreement as more fully set forth herein.

D.Bank has agreed to so amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.

Agreement

Now, Therefore, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

1.Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.

2.Amendment to Loan Agreement.

2.1Section 2.3 (Overadvances). Section 2.3 is amended by deleting the reference to “the Default Rate” therein and inserting in lieu thereof “a per annum rate equal to the rate that is otherwise applicable to Advances plus five percent (5.00%)”.

2.2Section 3.2(a) and (b) (Conditions Precedent to all Credit Extensions). Subsections (a) and (b) of Section 3.2 are amended in their entirety and replaced with the following:

“(a)receipt of the Notice of Borrowing and any materials and documents required by and in accordance with Section 3.4(a);

(b)the representations and warranties in this Agreement shall be true, accurate, and complete in all material respects on the date of the proposed Credit Extension and on the Funding Date of each Credit Extension; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or immediately result from the Credit Extension. Each Credit Extension is Borrower’s representation and warranty on that date that the representations and warranties in this Agreement remain true, accurate, and complete in all material respects; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date; and”

2.3Section 3.4(a) (Procedures for Borrowing). Section 3.4(a) is amended in its entirety and replaced with the following:

“(a)Subject to the prior satisfaction of all other applicable conditions to the making of an Advance set forth in this Agreement, an Advance shall be made upon Borrower’s irrevocable written notice delivered to Bank in the form of a Notice of Borrowing or without instructions if any Advances is necessary to meet Obligations which have become due, and such Notice of Borrowing shall indicate whether Borrower is requesting an Advance with respect to Eligible Accounts, Eligible Foreign Accounts, or Eligible Inventory, as applicable. The Notice of Borrowing shall be made by Borrower through Bank’s online banking program, provided, however, if Borrower is not utilizing Bank’s online banking program, then such Notice of Borrowing shall be in the form attached hereto as Exhibit C and shall be executed by an Authorized Signer. The Notice of Borrowing must be received by Bank prior to 12:00 p.m. Eastern time, (i) at least three (3) Business Days prior to the requested Funding Date, in the case of any LIBOR Advance, and (ii) on the requested Funding Date, in the case of a Prime Rate Advance, specifying: (1) the amount of the Advance; (2) the Currency in which such Advance shall be denominated; (3) the requested Funding Date; (4) whether the Advance is to be comprised of LIBOR Advances or Prime Rate Advances; and (5) the duration of the Interest Period applicable to any such LIBOR Advances included in such notice; provided that if the Notice of Borrowing shall fail to specify the duration of the Interest Period for any Advance comprised of LIBOR Advances, such Interest Period shall be one (1) month. In addition to such Notice of Borrowing, when a Streamline Period is not in effect, Borrower must promptly deliver to Bank by electronic mail or through Bank’s online banking program such reports and information, including without limitation, sales journals, cash receipts journals, accounts receivable aging reports, as Bank may request in its sole discretion.”

2.4Section 6.2 (a) and (b) (Financial Statements, Reports, Certificates). Subsections (a) and (b) of Section 6.2 are amended in their entirety and replaced with the following:

“(a)a Borrowing Base Report (and any schedules related thereto (i) with each request for an Advance, (ii) on the fifteenth (15^th) day (if the 15^th is not a Business Day, on the preceding Business Day) and last day of each month when a Streamline Period is not in effect, and (iii) within twenty (20) days after the end of each month when a Streamline Period is in effect;

(b)(1) within twenty (20) days after the end of each month, (A) monthly accounts receivable agings, aged by invoice date, (B) monthly accounts payable agings, aged by invoice date, and outstanding or held check registers, if any, and (C) monthly reconciliations of accounts receivable agings (aged by invoice date), transaction reports, Deferred Revenue report, and general ledger; and (2) perpetual inventory reports for Inventory valued on a first-in, first-out basis at the lower of cost or market (in accordance with GAAP) or such other inventory reports as are requested by Bank in its good faith business judgment (i) on the fifteenth (15^th) day (if the 15^th is not a Business Day, on the preceding Business Day) and last day of each month when a Streamline Period is not in effect, and (ii) within twenty (20) days after the end of each month when a Streamline Period is in effect;”

2.5Section 6.3(c) (Accounts Receivable; Collection of Accounts). Subsection (c) of Section 6.3 is amended in its entirety and replaced with the following:

“(c)Collection of Accounts. Borrower shall direct Account Debtors to deliver or transmit all proceeds of Accounts into a lockbox account, or such other “blocked account” as specified by Bank (either such account, the “Cash Collateral Account”). Whether or not an Event of Default has occurred and is continuing, Borrower shall immediately deliver all payments on and proceeds of Accounts to the Cash Collateral Account. All amounts received in the Cash Collateral Account shall be (i) subject to the Bank’s right to maintain a reserve pursuant to Section 6.3(g), applied to immediately reduce the Obligations when a Streamline Period is not in effect (unless Bank, in its sole discretion, elects not to so apply such amounts), or (ii) transferred on a daily basis to Borrower’s operating account with Bank when a Streamline Period is in effect. Borrower hereby authorizes Bank to transfer to the Cash Collateral Account any amounts that Bank reasonably determines are proceeds of the Accounts (provided that Bank is under no obligation to do so and this allowance shall in no event relieve Borrower of its obligations hereunder).”

2.6Section 6.3(e) (Accounts Receivable; Verification). Subsection (e) of Section 6.3 is amended in its entirety and replaced with the following:

“(e)Verifications; Confirmations; Credit Quality; Notifications. Bank may, from time to time, after consultation with the Borrower, verify and confirm directly with the respective Account Debtors the validity, amount and other matters relating to the Accounts, either in the name of Borrower or Bank or such other name as Bank may choose, and notify any Account Debtor of Bank’s security interest in such Account.”

2.7Section 6.3(g) (Accounts Receivable). Section 6.3 is hereby amended by inserting the following new subsection (g) immediately following subsection (f) thereof:

“(g)Reserves. Notwithstanding any terms in this Agreement to the contrary, at times when an Event of Default exists, Bank may hold any proceeds of the Accounts and any amounts in the Cash Collateral Account that are not applied to the Obligations pursuant to Section 6.3(c) above (including amounts otherwise required to be transferred to Borrower’s operating account with Bank when a Streamline Period is in effect) as a reserve to be applied to any Obligations regardless of whether such Obligations are then due and payable.”

2.8Section 6.6 (Access to Collateral; Books and Records). Section 6.6 is amended in its entirety and replaced with the following:

“6.6Access to Collateral; Books and Records. At reasonable times, on one (1) Business Day’s notice (provided no notice is required if an Event of Default has occurred and is continuing), Bank, or its agents, shall have the right to inspect the Collateral and the right to audit and copy Borrower’s Books. The foregoing inspections and audits shall be conducted no more often than once every twelve (12) months unless an Event of Default has occurred and is continuing in which case such inspections and audits shall occur as often as Bank shall determine is necessary. The foregoing inspections and audits shall be conducted at Borrower’s expense and the charge therefor shall be One Thousand Dollars ($1,000) per person per day (or such higher amount as shall represent Bank’s then-current standard charge for the same), plus reasonable out-of-pocket expenses. In the event Borrower and Bank schedule an audit more than five (5) days in advance, and Borrower cancels or seeks to or reschedules the audit with less than five (5) days written notice to Bank, then (without limiting any of Bank’s rights or remedies) Borrower shall reimburse Bank for any costs incurred by Bank, plus any out-of-pocket expenses directly relating to the cancellation or rescheduling.”

2.9Section 6.9 (Financial Covenants). Section 6.9 is amended in its entirety and replaced with the following:

“6.9Financial Covenants.

(a)EBITDA. Borrower shall achieve, measured as of the end of each fiscal quarter during the following periods, EBITDA of at least (loss not worse than) the following for the following periods:


Period	Minimum EBITDA (maximum loss)
Trailing three (3) month period ending December 31, 2016	($3,000,000)
Trailing six (6) month period ending March 31, 2017	($7,950,000)
Trailing nine (9) month period ending June 30, 2017	($9,400,000)
Trailing twelve (12) month period ending September 30, 2017	($8,800,000)
Trailing twelve (12) month period ending December 31, 2017	($4,250,000)

(b)Adjusted Quick Ratio. Maintain at all times, to be certified to Bank monthly as of the last day of each month, an Adjusted Quick Ratio of at least 1.25 to 1.00.”

2.10Section 6.14 (Online Banking). The following new Section 6.14 is hereby inserted immediately following Section 6.13:

“6.14Online Banking. Utilize Bank’s online banking platform for all matters reasonably requested by Bank which shall include, without limitation (and without request by Bank for the following matters), uploading information pertaining to Accounts and Account Debtors, requesting approval for exceptions, requesting Credit Extensions, and uploading financial statements and other reports required to be delivered pursuant to the terms of this Agreement.”

2.11Section 8.2(a) (Covenant Default). Section 8.2(a) is amended in its entirety and replaced with the following:

“(a)Borrower fails or neglects to perform any obligation in Sections 6.2 (provided, however, Borrower shall have ten (10) Business Days from the scheduled due date to cure any default under clauses 6.2(b)-(d) and 6.2(i)), 6.5, 6.7(a), 6.8(a), 6.9, 6.10(b), 6.12, 6.13, or violates any covenant in Section 7; or”

2.12Section 9.2 (Power of Attorney). Section 9.2 is amended in its entirety and replaced with the following:

“9.2Power of Attorney. Borrower hereby irrevocably appoints Bank as its lawful attorney-in-fact, exercisable following the occurrence of an Event of Default, to: (a) endorse Borrower’s name on any checks, payment instruments, or other forms of payment or security; (b) sign Borrower’s name on any invoice or bill of lading for any Account or drafts against Account Debtors; (c) demand, collect, sue, and give releases to any Account Debtor for monies due, settle and adjust disputes and claims about the Accounts directly with Account Debtors, and compromise, prosecute, or defend any action, claim, case, or proceeding about any Collateral (including filing a claim or voting a claim in any bankruptcy case in Bank’s or Borrower’s name, as Bank chooses); (d) make, settle, and adjust all claims under Borrower’s insurance policies; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, or other claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same; and (f) transfer the Collateral into the name of Bank or a third party as the Code permits. Borrower hereby appoints Bank as its lawful attorney-in-fact to sign Borrower’s name on any documents necessary to perfect or continue the perfection of Bank’s security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations have been satisfied in full and Bank has no further obligation to make Credit Extensions hereunder. Bank’s foregoing appointment as Borrower’s attorney in fact, and all of Bank’s rights and powers, coupled with an interest, are irrevocable until all Obligations have been fully repaid and performed and Bank has no further obligation to make Credit Extensions hereunder.”

2.13Section 13 (Definitions). The following terms and their respective definitions set forth in Section 13.1 is amended in their entirety and replaced with the following:

“Borrowing Base” is (a) eighty percent (80%) of Eligible Accounts, plus (b) eighty percent (80%) of Eligible Foreign Accounts (provided, however, Eligible Foreign Accounts that are billed in a Foreign Currency shall have an advance rate of seventy percent (70%)), provided, that, the availability under this subsection (b) plus the availability under subsection (c) below shall not exceed seventy-five percent (75%) of the Borrowing Base, plus (c) (i) when a Streamline Period is not in effect, the lesser of eighty percent (80%) of Eligible Specified Accounts or One Million Dollars ($1,000,000) and (ii) during a Streamline Period, eighty percent (80%) of Eligible Specified Accounts (and with respect to subsections (c)(i) and (c)(ii) hereof, when added to the availability under subsection (b) above, in each case subject to the overall cap set forth in subsection (b) above), plus (d) the lesser of thirty-five percent (35%) of the value of Borrower’s Eligible Inventory (valued at the lower of cost or wholesale fair market value) or Three Million Dollars ($3,000,000), as determined by Bank from Borrower’s most recent Borrowing Base Report (and as may subsequently be updated by Bank in Bank’s sole discretion based upon information received by Bank including, without limitation, Accounts that are paid and/or billed following the date of the Borrowing Base Report); provided, however, that Bank may decrease the foregoing amounts and percentages in its good faith business judgment based on events, conditions, contingencies, or risks which, as determined by Bank, may adversely affect the Collateral.

“LIBOR” means, for any Interest Rate Determination Date with respect to an Interest Period for any Advance to be made, continued as or converted into a LIBOR Advance, the rate of interest per annum determined by Bank to be the per annum rate of interest at which deposits in Dollars are offered to Bank in the London interbank market (rounded upward, if necessary, to the nearest 0.0001%) in which Bank customarily participates at 11:00 a.m. (local time in such interbank market) two (2) Business Days prior to the first day of such Interest Period for a period approximately equal to such Interest Period and in an amount approximately equal to the amount of such Advance; provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Agreement.

“Prime Rate” is the rate of interest per annum from time to time published in the money rates section of The Wall Street Journal or any successor publication thereto as the “prime rate” then in effect; provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Agreement; and provided further that if such rate of interest, as set forth from time to time in the money rates section of The Wall Street Journal, becomes unavailable for any reason as determined by Bank, the “Prime Rate” shall mean the rate of interest per annum announced by Bank as its prime rate in effect at its principal office in the State of California (such Bank announced Prime Rate not being intended to be the lowest rate of interest charged by Bank in connection with extensions of credit to debtors); provided that, in the event such rate of interest is less than zero, such rate shall be deemed to be zero for purposes of this Agreement.

“Revolving Line Maturity Date” is January 28, 2018.

2.14Section 13 (Definitions). The preamble in the definition of Eligible Accounts set forth in Section 13.1 is deleted in its entirety and replaced with the following:

“Eligible Accounts” means Accounts which arise in the ordinary course of Borrower’s business that meet all Borrower’s representations and warranties in Section 5.3 and are due and owing from Account Debtors deemed creditworthy by Bank in its good faith business judgment. Bank reserves the right upon prior written notice to

Borrower at any time after the Effective Date to adjust any of the criteria set forth below and to establish new criteria in its good faith business judgment. Unless Bank otherwise agrees in writing, Eligible Accounts shall not include:”

2.15Section 13 (Definitions). The following new defined term is hereby inserted in Section 13.1 in the appropriate alphabetical order:

“Borrowing Base Report” is that certain report of the value of certain Collateral in the form attached hereto as Exhibit E.

2.16Section 13 (Definitions). The following defined terms set forth in Section 13.1 are deleted in their entirety:

“Transaction Report” is the Bank’s standard reporting package provided by Bank to Borrower.

“Unfinanced Capital Expenditures” means, with respect to any Person for any period, the aggregate of all Capital Expenditures by such Person and its Subsidiaries during such period that are not financed or funded using proceeds from (a) the issuance of additional equity interests of Borrower, (b) Subordinated Debt, (c) specific equipment financing, (d) other capital permitted by Bank, and in all instances that are Capital Expenditures as determined in accordance with GAAP, or (e) government grants or other incentives.

2.17Exhibit B (Compliance Certificate). The Compliance Certificate attached to the Loan Agreement as Exhibit B is amended in its entirety and replaced with the Compliance Certificate in the form of Exhibit B attached hereto.

2.18Exhibit E (Borrowing Base Report). The Borrowing Base Report attached hereto as Exhibit E is hereby inserted immediately following Exhibit D of the Loan Agreement.

3.Limitation of Amendments.

3.1The amendments set forth in Section 2 above are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan Document.

3.2This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.

4.Representations and Warranties. To induce Bank to enter into this Amendment, Borrower hereby represents and warrants to Bank as follows:

4.1Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing;

4.2Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;

4.3The organizational documents of Borrower delivered to Bank on the Effective Date remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;

4.4The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;

4.5The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;

4.6The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority,

or subdivision thereof, binding on Borrower, except as already has been obtained or made; and

4.7This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights.

5.Updated Perfection Certificate. Borrower has delivered an updated Perfection Certificate dated on or about the date of this Amendment (the “Updated Perfection Certificate”), which Updated Perfection Certificate shall supersede in all respects that certain Perfection Certificate dated as of August 31, 2014. Borrower and Bank acknowledge and agree that all references in the Loan Agreement to the “Perfection Certificate” shall hereinafter be deemed to be a reference to the Updated Perfection Certificate.

6.No Defenses of Borrower. Borrower hereby acknowledges and agrees that Borrower has no offsets, defenses, claims, or counterclaims against Bank with respect to the Obligations, or otherwise, and that if Borrower now has, or ever did have, any offsets, defenses, claims, or counterclaims against Bank, whether known or unknown, at law or in equity, all of them are hereby expressly WAIVED and Borrower hereby RELEASES Bank from any liability thereunder.

7. Integration. This Amendment and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements. All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Amendment and the Loan Documents merge into this Amendment and the Loan Documents.

8.Counterparts. This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.

9.Fees and Expenses. Borrower agrees to promptly pay Bank, upon receipt of an invoice, Bank’s legal fees and expenses incurred in connection with this Amendment.

10.Effectiveness. As a condition precedent to the effectiveness of this Amendment and the Bank’s obligation to make the Advances under the Revolving Line, the Bank shall have received the following documents prior to or concurrently with this Amendment, each in form and substance satisfactory to Bank:

10.1this Amendment duly executed on behalf of Borrower;

10.2the Acknowledgement of Amendment and Reaffirmation of Guaranty substantially in the form attached hereto as Schedule 1, duly executed and delivered by the Guarantor;

10.3a duly executed officer’s certificate or secretary’s certificate, attaching copies of each of (i) the organizational documents of Borrower as in effect on the date hereof, (ii) the resolutions of Borrower authorizing the execution and delivery of this Amendment, the other documents executed in connection herewith and Borrower’s performance of all of the transactions contemplated hereby, and (iii) an incumbency certificate giving the name and bearing a specimen signature of each individual who shall be so authorized on behalf of Borrower;

10.4a good standing certificate of Borrower, certified by the Secretary of State of the jurisdiction of formation and each jurisdiction in which Borrower is qualified to do business, dated as of a date no earlier than thirty (30) days prior to the date hereof;

10.5certified copies, dated as of a recent date, of financing statement and other lien searches of Borrower and Guarantor, as Bank may request and which shall be obtained by Bank, accompanied by written evidence (including any UCC termination statements) that the Liens revealed in any such searched either (i) will be terminated prior to or in connection with the execution of this Amendment, or (ii) in the sole discretion of Bank, will constitute Permitted Liens;

10.6evidence satisfactory to Bank that the insurance policies required for Borrower are in full force and effect, together with appropriate evidence showing lender loss payable and/or additional insured clauses or endorsements in favor of Bank;

10.7the Updated Perfection Certificate executed by Borrower, together with the duly executed original signature thereto; and

10.8Borrower’s payment of a fully earned, non-refundable amendment fee in an amount equal to Fifty Thousand Dollars ($50,000), payable on the date of this Amendment.

[Signature page follows.]

In Witness Whereof, the parties hereto have caused this Amendment to be duly executed and delivered as of the date first written above.

BANK

BORROWER

SILICON VALLEY BANK

By: _/s/ Christopher Leary________

Name: __ Christopher Leary ______

Title: Director_________________

ASPEN AEROGELS, INC.

By: /s/ John F. Fairbanks_________

Name: _ John F. Fairbanks _______

Title: Chief Financial Officer ____

Schedule 1

ACKNOWELDGMENT OF AMENDMENT
AND REAFFIRMATION OF GUARANTY

Section 1.Guarantor hereby acknowledges and confirms that it has reviewed and approved the terms and conditions of the Fourth Amendment to Amended and Restated Loan and Security Agreement dated as of even date herewith (“the “Amendment”).

Section 2.Guarantor hereby consents to the Amendment and agrees that the Guaranty relating to the Obligations of Borrower under the Loan Agreement shall continue in full force and effect, shall be valid and enforceable and shall not be impaired or otherwise affected by the execution of the Amendment or any other document or instruction delivered in connection herewith.

Section 3.Guarantor represents and warrants that, after giving effect to the Amendment, all representations and warranties contained in the Guaranty are true, accurate and complete as if made the date hereof.

Dated as of January 27, 2017.

GUARANTOR:

ASPEN AEROGELS RHODE ISLAND LLC

By: /s/ John F. Fairbanks ________

Name: _ John F. Fairbanks ______

Title: __ Chief Financial Officer _

EXHIBIT B

COMPLIANCE CERTIFICATE

TO:SILICON VALLEY BANKDate:
FROM: ASPEN AEROGELS, INC.

The undersigned authorized officer of Aspen Aerogels, Inc. (“Borrower”) certifies that under the terms and conditions of the Amended and Restated Loan and Security Agreement between Borrower and Bank (as amended and in effect, the “Agreement”), (1) Borrower is in complete compliance for the period ending _______________ with all required covenants except as noted below, (2) there are no Events of Default, (3) all representations and warranties in the Agreement are true and correct in all material respects on this date except as noted below; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, (4) Borrower, and each of its Subsidiaries, has timely filed all required tax returns and reports, and Borrower has timely paid all foreign, federal, state and local taxes, assessments, deposits and contributions owed by Borrower except as otherwise permitted pursuant to the terms of Section 5.9 of the Agreement, and (5) no Liens have been levied or claims made against Borrower or any of its Subsidiaries, if any, relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Bank. Attached are the required documents supporting the certification. The undersigned certifies that these are prepared in accordance with GAAP consistently applied from one period to the next except as explained in an accompanying letter or footnotes. The undersigned acknowledges that no borrowings may be requested at any time or date of determination that Borrower is not in compliance with any of the terms of the Agreement, and that compliance is determined not just at the date this certificate is delivered. Capitalized terms used but not otherwise defined herein shall have the meanings given them in the Agreement.


Please indicate compliance status by circling Yes/No under “Complies” column.

Reporting Covenant	Required	Complies

Monthly financial statements with Compliance Certificate	Monthly within 30 days	Yes No
Quarterly financial statements	Quarterly within 45 days	Yes No
Annual financial statement (CPA Audited) + CC	FYE within 150 days	Yes No
10‑Q, 10‑K and 8-K	Within 5 days after filing with SEC	Yes No
A/R & A/P Agings, and Deferred Revenue reports	Monthly within 20 days	Yes No
Borrowing Base Reports and Inventory reports	15^th and last Business Day of each month (monthly within 20 days when a Streamline Period is in effect) and with each request for a Credit Extension;	Yes No
Projections	FYE within 30 days	Yes No

The following Intellectual Property was registered after the Effective Date (if no registrations, state “None”)____________________________________________________________________________


Financial Covenant	Required	Actual	Complies

Maintain as indicated:
Minimum EBITDA	*	$	Yes No
Minimum Adjusted Quick Ratio	1.25:1.00	:1.00	Yes No

*See Section 6.9(a)


Performance Pricing		Applies

Adjusted Quick Ratio at least 1.50:1.00	Prime + 0.75% (Eligible Accounts) or Prime + 1.25% (Eligible Foreign Accounts and Eligible Inventory); LIBOR + 3.75% (Eligible Accounts) or LIBOR +4.25% (Eligible Foreign Accounts and Eligible Inventory)	Yes No
Adjusted Quick Ratio less than 1.50:1.00	Prime + 1.25% (Eligible Accounts); Prime + 1.75% (Eligible Foreign Accounts and Eligible Inventory)	Yes No

The following financial covenant analyses and information set forth in Schedule 1 attached hereto are true and accurate as of the date of this Certificate.

The following are the exceptions with respect to the certification above: (If no exceptions exist, state “No exceptions to note.”)

---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASPEN AEROGELS, INC.

By:
Name:
Title:

BANK USE ONLY

Received by: _____________________
authorized signer

Date: _________________________

Verified: ________________________
authorized signer

Date: _________________________

Compliance Status:Yes No

Schedule 1 to Compliance Certificate

Financial Covenants of Borrower

In the event of a conflict between this Schedule and the Loan Agreement, the terms of the Loan Agreement shall govern.

I.EBITDA (Section 6.9(a))

Required:

Borrower shall achieve, measured as of the end of each fiscal quarter during the following periods, EBITDA of at least (loss not worse than) the following for the following periods:


Period	Minimum EBITDA (maximum loss)
Trailing three (3) month period ending December 31, 2016	($3,000,000)
Trailing six (6) month period ending March 31, 2017	($7,950,000)
Trailing nine (9) month period ending June 30, 2017	($9,400,000)
Trailing twelve (12) month period ending September 30, 2017	($8,800,000)
Trailing twelve (12) month period ending December 31, 2017	($4,250,000)

Actual:


A.	Net Income	$
B.	To the extent included in the determination of Net Income
	1.The provision for income taxes	$
	2.Depreciation expense	$
	3.Amortization expense	$
	4.Net Interest Expense	$
	5.Non-cash stock compensation expense	$
	6.The sum of lines 1 through 5	$
C.	EBITDA (line A plus line B.6)

Is line C equal to or greater than $___________?

No, not in compliance Yes, in compliance

II.Minimum Adjusted Quick Ratio (Section 6.9(b))

Required:

Maintain at all times, to be certified to Bank monthly as of the last day of each month, an Adjusted Quick Ratio of at least 1.25 to 1.00.

Actual:


A.	Aggregate value of the unrestricted cash of Borrower maintained with Bank	$
B.	Aggregate value of accounts receivable of Borrower, net of allowances for bad debt	$
C.	Quick Assets (the sum of lines A and B)	$
D.	Aggregate value of Obligations to Bank	$
E.	Without duplication of line D, the aggregate value of liabilities of Borrower (including all Indebtedness) that matures within one (1) year, but excluding all Subordinated Debt	$
F.	Current Liabilities (the sum of lines D and E)	$
G.	Aggregate value of all amounts received or invoiced by Borrower in advance of performance under contracts and not yet recognized as revenue	$
H.	Line F minus line G	$
I.	Adjusted Quick Ratio (line C divided by line H)	:1.00

Is line I equal to or greater than 1.25 to 1.00?

No, not in compliance Yes, in compliance

EXHIBIT E

BORROWING BASE REPORT

[To be provided by Bank]

EX-31.1 3 aspn-ex311_29.htm EX-31.1 aspn-ex311_29.htm

Exhibit 31.1

CERTIFICATIONS UNDER SECTION 302

I, Donald R. Young, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Aspen Aerogels, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2017

/s/ Donald R. Young

Donald R. Young

President and Chief Executive Officer

(principal executive officer)

EX-31.2 4 aspn-ex312_28.htm EX-31.2 aspn-ex312_28.htm

Exhibit 31.2

CERTIFICATIONS UNDER SECTION 302

I, John F. Fairbanks, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Aspen Aerogels, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 4, 2017				/s/ John F. Fairbanks
				John F. Fairbanks
				Vice President, Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer)

EX-32 5 aspn-ex32_27.htm EX-32 aspn-ex32_27.htm

Exhibit 32

CERTIFICATIONS UNDER SECTION 906

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Aspen Aerogels, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the quarter ended March 31, 2017 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 4, 2017				/s/ Donald R. Young
				Donald R. Young
				President and Chief Executive Officer (principal executive officer)

Dated: May 4, 2017				/s/ John F. Fairbanks
				John F. Fairbanks
				Vice President, Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer)

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 6 aspn-20170331.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares aspn:Subsidiary aspn:Segment aspn:Installment pure 0001145986 2017-01-01 2017-03-31 0001145986 2017-05-01 0001145986 2017-03-31 0001145986 2016-12-31 0001145986 2016-01-01 2016-03-31 0001145986 2015-12-31 0001145986 2016-03-31 0001145986 aspn:TwoThousandFourteenEquityPlanMember us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001145986 aspn:TwoThousandFourteenEquityPlanMember aspn:NonQualifiedStockOptionsMember 2017-01-01 2017-03-31 0001145986 us-gaap:CostOfSalesMember 2017-01-01 2017-03-31 0001145986 us-gaap:CostOfSalesMember 2016-01-01 2016-03-31 0001145986 us-gaap:ResearchAndDevelopmentExpenseMember 2017-01-01 2017-03-31 0001145986 us-gaap:ResearchAndDevelopmentExpenseMember 2016-01-01 2016-03-31 0001145986 us-gaap:SellingAndMarketingExpenseMember 2017-01-01 2017-03-31 0001145986 us-gaap:SellingAndMarketingExpenseMember 2016-01-01 2016-03-31 0001145986 us-gaap:GeneralAndAdministrativeExpenseMember 2017-01-01 2017-03-31 0001145986 us-gaap:GeneralAndAdministrativeExpenseMember 2016-01-01 2016-03-31 0001145986 aspn:TwoThousandFourteenEquityPlanMember 2017-01-01 2017-01-02 0001145986 aspn:TwoThousandFourteenEquityPlanMember 2017-01-02 0001145986 aspn:TwoThousandFourteenEquityPlanMember 2017-03-31 0001145986 aspn:TwoThousandOneEquityIncentivePlanMember 2017-03-31 0001145986 country:US 2017-01-01 2017-03-31 0001145986 country:US 2016-01-01 2016-03-31 0001145986 aspn:InternationalMember 2017-01-01 2017-03-31 0001145986 aspn:InternationalMember 2016-01-01 2016-03-31 0001145986 aspn:AccountingStandardsUpdateTwoThousandSixteenZeroNineMember 2017-01-01 0001145986 us-gaap:ConstructionInProgressMember 2017-03-31 0001145986 us-gaap:ConstructionInProgressMember 2016-12-31 0001145986 us-gaap:BuildingMember 2017-03-31 0001145986 us-gaap:BuildingMember 2016-12-31 0001145986 us-gaap:MachineryAndEquipmentMember 2017-03-31 0001145986 us-gaap:MachineryAndEquipmentMember 2016-12-31 0001145986 aspn:ComputerEquipmentAndSoftwareMember 2017-03-31 0001145986 aspn:ComputerEquipmentAndSoftwareMember 2016-12-31 0001145986 us-gaap:BuildingMember 2017-01-01 2017-03-31 0001145986 us-gaap:MachineryAndEquipmentMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001145986 us-gaap:MachineryAndEquipmentMember us-gaap:MaximumMember 2017-01-01 2017-03-31 0001145986 aspn:ComputerEquipmentAndSoftwareMember 2017-01-01 2017-03-31 0001145986 stpr:GA us-gaap:ConstructionInProgressMember 2017-03-31 0001145986 stpr:GA us-gaap:ConstructionInProgressMember 2016-12-31 0001145986 aspn:BasfMember us-gaap:SupplyCommitmentMember 2017-01-01 2017-03-31 0001145986 aspn:ThirdPartyLenderMember us-gaap:SupplyCommitmentMember aspn:BasfMember aspn:PlantTwoMember us-gaap:MinimumMember 2017-01-01 2017-03-31 0001145986 us-gaap:MaximumMember us-gaap:SupplyCommitmentMember aspn:BasfMember 2017-01-01 2017-03-31 0001145986 aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:RevolvingCreditFacilityMember 2017-01-26 2017-01-27 0001145986 aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember 2017-03-31 0001145986 aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember 2017-01-01 2017-03-31 0001145986 us-gaap:MinimumMember us-gaap:PrimeRateMember aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember 2017-01-01 2017-03-31 0001145986 us-gaap:MaximumMember us-gaap:PrimeRateMember aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember 2017-01-01 2017-03-31 0001145986 us-gaap:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember 2017-01-01 2017-03-31 0001145986 us-gaap:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember 2017-01-01 2017-03-31 0001145986 aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:RevolvingCreditFacilityMember 2017-03-31 0001145986 aspn:SiliconValleyBankCreditFacilityMember aspn:AmendedAndRestatedLoanAndSecurityAgreementMember us-gaap:RevolvingCreditFacilityMember 2016-12-31 0001145986 aspn:CommonStockOptionsMember 2017-01-01 2017-03-31 0001145986 aspn:CommonStockOptionsMember 2016-01-01 2016-03-31 0001145986 us-gaap:RestrictedStockUnitsRSUMember 2017-01-01 2017-03-31 0001145986 us-gaap:RestrictedStockUnitsRSUMember 2016-01-01 2016-03-31 0001145986 aspn:CommonStockWarrantsMember 2017-01-01 2017-03-31 0001145986 aspn:CommonStockWarrantsMember 2016-01-01 2016-03-31 0001145986 us-gaap:RestrictedStockMember 2017-01-01 2017-03-31 0001145986 us-gaap:RestrictedStockMember 2016-01-01 2016-03-31 10-Q false 2017-03-31 2017 Q1 ASPN ASPEN AEROGELS INC 0001145986 --12-31 Accelerated Filer 23508417

11228000

18086000

17248000

17535000

15132000

12868000

1192000

1697000

44800000

50186000

82719000

84394000

97000

89000

127616000

134669000

14169000

13065000

4112000

3987000

789000

1043000

20000

35000

19090000

18130000

4000

1082000

971000

20172000

19105000

534346000

533088000

-426902000

-417524000

107444000

115564000

127616000

134669000

83000 93000

0.00001

5000000

0.00001

125000000

23508417

23369838

23508417

23369838

22326000

32286000

676000

535000

23002000

32821000

20470000

25992000

311000

302000

2221000

6527000

1576000

1310000

3110000

3062000

6587000

3913000

11273000

8285000

-9052000

-1758000

-26000

-39000

-26000

-39000

-9078000

-1797000

-0.39

-0.08

23257541

23063471

2676000

2410000

1244000

1370000

22000

1000

13000

-442000

2291000

2264000

-393000

-497000

-966000

2238000

1508000

125000

-2203000

-254000

-542000

-22000 -15000

-4419000

-214000

2146000

3128000

-2146000

-3128000

7000

23000

286000

82000

-293000

-105000

-6858000

-3447000

32804000

29357000

40000

52000

-1134000

484000

292000

<div> (1) Description of Business and Basis of Presentation Nature of Business Aspen Aerogels, Inc. (the Company) is an aerogel technology company that designs, develops and manufactures innovative, high-performance aerogel insulation used primarily in the energy infrastructure and building materials markets. The Company also conducts research and development related to aerogel technology supported by funding from several agencies of the U.S. government and other institutions in the form of research and development contracts. The Company maintains its corporate offices in Northborough, Massachusetts. The Company has three wholly owned subsidiaries: Aspen Aerogels Rhode Island, LLC, Aspen Aerogels Germany, GmbH and Aspen Aerogels Georgia, LLC. Unaudited Interim Financial Information The accompanying unaudited interim consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes in our Annual Report on Form 10-K for the year ended December 31, 2016 (the Annual Report), filed with the Securities and Exchange Commission on March 2, 2017. In the opinion of the Company’s management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and include all adjustments that are of a normal recurring nature and necessary for the fair statement of the Company’s financial position as of March 31, 2017 and the results of its operations for the three months ended March 31, 2017 and 2016 and the cash flows for the three month periods then ended. The Company has evaluated events through the date of this filing. The results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017 or any other period. There have been no changes to the Company’s significant accounting policies described in the Annual Report that have had a material impact on the Company’s consolidated financial statements and notes thereto.</div>

<div> (2) Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements, which have been prepared in accordance with U.S. GAAP, include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of the consolidated financial statements requires the Company to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions include allowances for doubtful accounts, sales returns and allowances, product warranty costs, inventory valuation, the carrying amount of property and equipment, stock-based compensation and deferred income taxes. The Company evaluates its estimates and assumptions on an on-going basis using historical experience and other factors, including the current economic environment, which are believed to be reasonable under the circumstances. Management adjusts such estimates and assumptions when facts and circumstances dictate. Illiquid credit markets, volatile equity markets and declines in business investment increase the uncertainty inherent in such estimates and assumptions. As future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Changes in these estimates resulting from continuing changes in the economic environment will be reflected in the financial statements in future periods. Cash and Cash Equivalents Cash equivalents include short-term, highly liquid instruments, which consist of money market accounts. All cash and cash equivalents are maintained with major financial institutions in North America. Deposits with these financial institutions may exceed the amount of insurance provided on such deposits; however, these deposits typically may be redeemed upon demand and, therefore, bear minimal risk. Revenue Recognition The Company recognizes revenue from the sale of products and performance of research and development services. Revenue is recognized when all of the following criteria are met: persuasive evidence of an arrangement exists, the price to the buyer is fixed or determinable, delivery has occurred or services have been provided, and collectability is reasonably assured. Product Revenue Product revenue is recognized upon transfer of title and risk of loss, which is upon shipment or delivery. The Company’s customary shipping terms are free on board (FOB) shipping point. The Company records deferred revenue for product sales when (i) the Company has delivered products but other revenue recognition criteria have not been satisfied or (ii) payments have been received in advance of products being delivered. Research Services Revenue The Company performs research services under contracts with various government agencies and other institutions. The Company records revenue earned on research services contracts using the percentage-of-completion method in two ways: (1) for firm-fixed-price contracts, the Company accrues that portion of the total contract price that is allocable, on the basis of the Company’s estimates of costs incurred to date to total contract costs; and (2) for cost-plus-fixed-fee contracts, the Company records revenue that is equal to total payroll cost incurred times a stated factor plus reimbursable expenses, to a stated upper limit. The primary cost is the labor effort expended in completing research, and the only deliverable, other than the labor hours expended, is reporting of research results to the customer. Because the input measure of labor hours expended is also reflective of the output measure, it is a reliable means to measure the extent of progress towards completion. Revisions in cost estimates and fees during the course of the contract are reflected in the accounting period in which the facts that require the revisions become known. Contract costs and rates used to allocate overhead to contracts are subject to audit by the respective contracting government agency. Adjustments to revenue as a result of audit are recorded in the period they become known. To date, adjustments to revenue as a result of audit have been insignificant. Stock-based Compensation Stock-based compensation expense is measured at the grant date based on the fair value of the award. Expense is recognized on a straight-line basis over the requisite service period for all awards with service conditions. For performance-based awards, the grant date fair value is recognized as expense when the condition is probable of being achieved, and then on a graded basis over the requisite service period. The Company uses the Black-Scholes option-pricing model to determine the fair value of service-based option awards, which requires a number of complex and subjective assumptions including fair value of the underlying security, the expected volatility of the underlying security, a risk-free interest rate and the expected term of the option. The fair value of restricted stock and restricted stock unit grants is determined using the closing trading price of the Company’s common stock on the date of grant. The fair value of awards containing market conditions is determined using a Monte Carlo simulation model based upon the terms of the conditions, the expected volatility of the underlying security, and other relevant factors. During the three months ended March 31, 2017, the Company granted 481,373 restricted common stock units (RSUs) and non-qualified stock options (NSOs) to purchase 320,571 shares of common stock to employees under the 2014 Employee, Director and Consultant Equity Incentive Plan (the 2014 Equity Plan). The employee RSUs and NSOs will vest over a three year period. Stock-based compensation is included in cost of sales or operating expenses, as applicable, and consists of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">777</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,244</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Effective January 1, 2017, the Company adopted the provision of Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU 2016-09) related to the timing of accounting for the forfeitures of share based awards using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of January 1, 2017 of $0.3 million.  Effective January 1, 2017, the Company will record the impact of forfeitures of service based awards at the time an award is forfeited.   Pursuant to the “evergreen” provisions of the 2014 Equity Plan, the number of shares of common stock authorized for issuance under the plan automatically increased by 467,396 shares to 6,536,597 shares effective January 1, 2017. As of March 31, 2017, 3,244,691 shares of common stock were reserved for issuance upon the exercise or vesting, as appropriate, of outstanding stock-based awards granted under the 2014 Equity Plan. In addition, as of March 31, 2017, 92,947 shares of common stock were reserved for issuance upon the exercise of outstanding stock options granted under the Company’s 2001 Equity Incentive Plan, as amended (the 2001 Equity Plan). Any cancellations or forfeitures of the options outstanding under the 2001 Equity Plan will result in the shares reserved for issuance upon exercise of such options becoming available for grant under the 2014 Equity Plan. As of March 31, 2017, there were 2,485,081 shares of common stock available for grant under the 2014 Equity Plan. Earnings per Share The Company calculates net loss per common share based on the weighted-average number of common shares outstanding during each period. Potential common stock equivalents are determined using the treasury stock method. The weighted-average number of common shares included in the computation of diluted net income (loss) gives effect to all potentially dilutive common equivalent shares, including outstanding stock options, RSUs and warrants. Common equivalent shares are excluded from the computation of diluted net income (loss) per share if their effect is antidilutive. Segments Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company’s chief operating decision maker reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. Information about the Company’s total revenues, based on shipment destination or services location, is presented in the following table:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,130</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,413</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,872</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,002</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,821</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Warranty Costs The Company provides warranties for its products and records the estimated cost within cost of sales in the period that the related revenue is recorded. The Company’s standard warranty period extends to one year from the date of shipment. The standard warranties provide that the Company’s products will be free from defects in material and workmanship, and will, under normal use, conform to the specifications for the product. The Company’s products may be utilized in systems that may involve new technical demands and new configurations. As such, the Company regularly reviews and assesses whether warranty reserves shall be recorded in the period the related revenue is recorded.  For an initial shipment of product in a system with new technical demands or configurations and where the Company is unsure of meeting the customer’s specifications, the Company will defer the recognition of product revenue and related costs until written customer acceptance is obtained. During the three months ended March 31, 2017, the Company recorded warranty expense of $0.9 million.  This specific warranty charge was related to a product claim for a specific product application issue. Recently Issued Accounting Standards In March 2016, the FASB issued ASU 2016-09. The amendment is to simplify several aspects of the accounting for share-based payment transactions including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. For public entities, the amendments in ASU 2016-09 are effective for interim and annual reporting periods beginning after December 15, 2016. The Company has adopted this standard effective January 1, 2017.  The provision of ASU 2016-09 related to the timing of accounting for the forfeitures of share based awards was adopted using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of January 1, 2017 of $0.3 million. The other provisions of ASU 2016-09 have been adopted prospectively.   In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). FASB ASU 2016-02 changes the accounting for leases and includes a requirement to record all leases on the consolidated balance sheets as assets and liabilities. This update is effective for fiscal years beginning after December 15, 2018. Early application is permitted. The Company has not yet selected a transition method and is evaluating the effect the updated standard will have on its consolidated financial statements and related disclosures. In August 2015, the FASB issued a deferral of ASU 2014-09, Revenue from Contracts with Customers. The standard will eliminate the transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principle based approach for determining revenue recognition. As a result of the deferral, public entities are required to apply the revenue recognition standard for the annual reporting period beginning on or after December 15, 2017, including interim periods within that annual reporting period. Early application is permitted only as of annual and interim periods in fiscal years beginning after December 15, 2016. The Company expects to adopt the modified retrospective method and is evaluating the effect that the updated standard will have on its consolidated financial statements and related disclosures. In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), which, for entities that do not measure inventory using the last-in, first-out (LIFO) or retail inventory method, changes the measurement principle for inventory from the lower of cost or market to lower of cost and net realizable value. The ASU also eliminates the requirement for these entities to consider replacement cost or net realizable value less an approximately normal profit margin when measuring inventory. Public entities are required to apply the standards for fiscal years beginning after December 15, 2016, including interim periods within those fiscal periods. The Company adopted this standard effective January 1, 2017.  There was no material impact on the Company’s consolidated financial statements and disclosures. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (ASU 2016-15). This amendment addresses eight classification issues related to the statement of cash flows. For public business entities, the amendments in ASU 2016-15 are effective for public business entities for annual and interim periods in fiscal years beginning after December 15, 2017. Early adoption is permitted, including adoption in an interim period. The Company has not yet selected a transition method and is evaluating the effect the updated standard will have on its consolidated financial statements and related disclosures.  </div>

<div> (4) Property, Plant and Equipment, Net Property, plant and equipment consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">life</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,216</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,139</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,929</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,901</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,659</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-10 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,817</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,679</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,332</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,378</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,613</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,984</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,719</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,394</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Depreciation expense was $2.7 million and $2.4 million for the three months ended March 31, 2017 and 2016, respectively. Construction in progress totaled $11.2 million and $11.1 million at March 31, 2017 and December 31, 2016, respectively, which included engineering designs and other pre-construction costs for the planned manufacturing facility in Statesboro, Georgia of $7.2 million at March 31, 2017 and December 31, 2016.</div>

<div> (8) Net Loss Per Share The computation of basic and diluted net loss per share consists of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">share and per share data)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,078</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,797</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares outstanding, basic and diluted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,257,541</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,063,471</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share, basic and diluted</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.39</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.08</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> </table></div>   Potentially dilutive common shares that were excluded from the computation of diluted net loss per share because they were anti-dilutive consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,382,710</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,879</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted common stock units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">954,928</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">759,510</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted common stock awards</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,277</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,130</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,491,030</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,844,650</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   In the table above, anti-dilutive shares consist of those common stock equivalents that have (i) an exercise price above the average stock price for the period or (ii) related average unrecognized stock compensation expense sufficient to buy back the entire amount of shares. The Company excludes the shares issued in connection with restricted stock awards from the calculation of basic weighted average common shares outstanding until the restrictions lapse.</div>

<div> Nature of Business Aspen Aerogels, Inc. (the Company) is an aerogel technology company that designs, develops and manufactures innovative, high-performance aerogel insulation used primarily in the energy infrastructure and building materials markets. The Company also conducts research and development related to aerogel technology supported by funding from several agencies of the U.S. government and other institutions in the form of research and development contracts. The Company maintains its corporate offices in Northborough, Massachusetts. The Company has three wholly owned subsidiaries: Aspen Aerogels Rhode Island, LLC, Aspen Aerogels Germany, GmbH and Aspen Aerogels Georgia, LLC.</div>

<div> Product Revenue Product revenue is recognized upon transfer of title and risk of loss, which is upon shipment or delivery. The Company’s customary shipping terms are free on board (FOB) shipping point. The Company records deferred revenue for product sales when (i) the Company has delivered products but other revenue recognition criteria have not been satisfied or (ii) payments have been received in advance of products being delivered. </div> <div> Research Services Revenue The Company performs research services under contracts with various government agencies and other institutions. The Company records revenue earned on research services contracts using the percentage-of-completion method in two ways: (1) for firm-fixed-price contracts, the Company accrues that portion of the total contract price that is allocable, on the basis of the Company’s estimates of costs incurred to date to total contract costs; and (2) for cost-plus-fixed-fee contracts, the Company records revenue that is equal to total payroll cost incurred times a stated factor plus reimbursable expenses, to a stated upper limit. The primary cost is the labor effort expended in completing research, and the only deliverable, other than the labor hours expended, is reporting of research results to the customer. Because the input measure of labor hours expended is also reflective of the output measure, it is a reliable means to measure the extent of progress towards completion. Revisions in cost estimates and fees during the course of the contract are reflected in the accounting period in which the facts that require the revisions become known. Contract costs and rates used to allocate overhead to contracts are subject to audit by the respective contracting government agency. Adjustments to revenue as a result of audit are recorded in the period they become known. To date, adjustments to revenue as a result of audit have been insignificant.</div>

<div> Stock-based Compensation Stock-based compensation expense is measured at the grant date based on the fair value of the award. Expense is recognized on a straight-line basis over the requisite service period for all awards with service conditions. For performance-based awards, the grant date fair value is recognized as expense when the condition is probable of being achieved, and then on a graded basis over the requisite service period. The Company uses the Black-Scholes option-pricing model to determine the fair value of service-based option awards, which requires a number of complex and subjective assumptions including fair value of the underlying security, the expected volatility of the underlying security, a risk-free interest rate and the expected term of the option. The fair value of restricted stock and restricted stock unit grants is determined using the closing trading price of the Company’s common stock on the date of grant. The fair value of awards containing market conditions is determined using a Monte Carlo simulation model based upon the terms of the conditions, the expected volatility of the underlying security, and other relevant factors. During the three months ended March 31, 2017, the Company granted 481,373 restricted common stock units (RSUs) and non-qualified stock options (NSOs) to purchase 320,571 shares of common stock to employees under the 2014 Employee, Director and Consultant Equity Incentive Plan (the 2014 Equity Plan). The employee RSUs and NSOs will vest over a three year period. Stock-based compensation is included in cost of sales or operating expenses, as applicable, and consists of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">777</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,244</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Effective January 1, 2017, the Company adopted the provision of Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting (ASU 2016-09) related to the timing of accounting for the forfeitures of share based awards using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of January 1, 2017 of $0.3 million.  Effective January 1, 2017, the Company will record the impact of forfeitures of service based awards at the time an award is forfeited.   Pursuant to the “evergreen” provisions of the 2014 Equity Plan, the number of shares of common stock authorized for issuance under the plan automatically increased by 467,396 shares to 6,536,597 shares effective January 1, 2017. As of March 31, 2017, 3,244,691 shares of common stock were reserved for issuance upon the exercise or vesting, as appropriate, of outstanding stock-based awards granted under the 2014 Equity Plan. In addition, as of March 31, 2017, 92,947 shares of common stock were reserved for issuance upon the exercise of outstanding stock options granted under the Company’s 2001 Equity Incentive Plan, as amended (the 2001 Equity Plan). Any cancellations or forfeitures of the options outstanding under the 2001 Equity Plan will result in the shares reserved for issuance upon exercise of such options becoming available for grant under the 2014 Equity Plan. As of March 31, 2017, there were 2,485,081 shares of common stock available for grant under the 2014 Equity Plan.</div>

<div> Segments Operating segments are identified as components of an enterprise about which separate, discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company’s chief operating decision maker reviews consolidated operating results to make decisions about allocating resources and assessing performance for the entire Company. The Company views its operations and manages its business as one operating segment. Information about the Company’s total revenues, based on shipment destination or services location, is presented in the following table:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,130</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,413</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,872</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,002</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,821</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Warranty Costs The Company provides warranties for its products and records the estimated cost within cost of sales in the period that the related revenue is recorded. The Company’s standard warranty period extends to one year from the date of shipment. The standard warranties provide that the Company’s products will be free from defects in material and workmanship, and will, under normal use, conform to the specifications for the product. The Company’s products may be utilized in systems that may involve new technical demands and new configurations. As such, the Company regularly reviews and assesses whether warranty reserves shall be recorded in the period the related revenue is recorded.  For an initial shipment of product in a system with new technical demands or configurations and where the Company is unsure of meeting the customer’s specifications, the Company will defer the recognition of product revenue and related costs until written customer acceptance is obtained. During the three months ended March 31, 2017, the Company recorded warranty expense of $0.9 million.  This specific warranty charge was related to a product claim for a specific product application issue.</div>

<div> Stock-based compensation is included in cost of sales or operating expenses, as applicable, and consists of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of product revenue</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">204</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">138</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">268</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">261</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">634</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">777</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,244</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Information about the Company’s total revenues, based on shipment destination or services location, is presented in the following table:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue:</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S.</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,130</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,413</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,872</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,408</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,002</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,821</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Property, plant and equipment consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Useful</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">life</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:25.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in progress</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,216</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,139</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,929</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,901</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,370</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,659</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3-10 years</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,817</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,679</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:11.76%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3 years</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,332</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,378</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated depreciation</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(74,613</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,984</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property, plant and equipment, net</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82,719</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84,394</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

<div> Potentially dilutive common shares that were excluded from the computation of diluted net loss per share because they were anti-dilutive consist of the following:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31,</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock options</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,382,710</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,952,879</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted common stock units</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">954,928</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">759,510</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock warrants</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">115</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted common stock awards</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">153,277</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,130</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,491,030</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,844,650</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>  </div>

481373

320571

P3Y

204000

192000

138000

140000

268000

261000

634000

777000

467396

6536597

3244691

92947

2485081

9130000

11413000

13872000

21408000

P1Y

900000

300000

3556000

3511000

11576000

9357000

11216000

11139000

23929000

23901000

114370000

113659000

7817000

7679000

157332000

156378000

74613000

71984000

P30Y

P3Y

P10Y

P3Y

2700000

2400000

7200000

2661000

2796000

1451000

1191000

2027-12-31 22000000 30000000 8 0.253

2018-01-28

20000000

The interest rate applicable to borrowings may be based on the prime rate or LIBOR. Prime rate-based rates vary from prime rate plus 0.75% per annum to prime rate plus 1.75% per annum, while LIBOR-based rates vary from LIBOR plus 3.75% per annum to LIBOR plus 4.25% per annum.

0.005

0.0075

0.0175

0.0375

0.0425

2400000

2700000

9700000

800000

500000

1251000

1125000

169000

154000

2382710

1952879

954928

759510

115

131

153277

132130

3491030

2844650

EX-101.SCH 7 aspn-20170331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100050 - Disclosure - Description of Business and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Inventories link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Property, Plant and Equipment, Net link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Accrued Expenses link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Deferred Rent link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Net Loss Per Share link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Description of Business and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Significant Accounting Policies (Tables) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Inventories (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Property, Plant and Equipment, Net (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Accrued Expenses (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Deferred Rent (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Net Loss Per Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Significant Accounting Policies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Significant Accounting Policies - Summary of Stock Based Compensation Included in Cost of Sales or Operating Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Significant Accounting Policies - Schedule of Total Revenues, Based on Shipment Destination or Research Services Location (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Inventories - Schedule of Inventories (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Property, Plant and Equipment, Net - Summary of Property, Plant and Equipment (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Deferred Rent - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Deferred Rent - Summary of Deferred Rent (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Common Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 aspn-20170331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 aspn-20170331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 aspn-20170331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable, net of allowances of $83 and $93 Accounts Receivable Net Current Inventories Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Property, plant and equipment, net Property Plant And Equipment Net Other long-term assets Other Assets Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued expenses Accrued Liabilities Current Deferred revenue Deferred Revenue Current Capital leases, current portion Capital Lease Obligations Current Total current liabilities Liabilities Current Capital leases, excluding current portion Capital Lease Obligations Noncurrent Deferred rent Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 6) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.00001 par value; 5,000,000 shares authorized, no shares issued and outstanding at March 31, 2017 and December 31, 2016 Preferred Stock Value Common stock, $0.00001 par value; 125,000,000 shares authorized, 23,508,417 and 23,369,838 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Allowance for doubtful accounts receivable and sales return reserve. Allowance for doubtful accounts Allowance For Doubtful Accounts Receivable And Sales Return Reserve Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Revenue: Revenues [Abstract] Product Sales Revenue Goods Net Research services Sales Revenue Services Net Total revenue Sales Revenue Net Cost of revenue: Cost Of Revenue [Abstract] Product Cost Of Goods Sold Research services Cost Of Services Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Sales and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Interest expense, net Interest Income Expense Nonoperating Net Total interest expense, net Nonoperating Income Expense Net loss Net Income Loss Net loss per share: Earnings Per Share [Abstract] Basic and diluted Earnings Per Share Basic And Diluted Weighted-average common shares outstanding: Weighted Average Number Of Shares Outstanding [Abstract] Basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Lease incentives premiums and discounts net. Increase decrease in deferred rent credit noncurrent. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation Depletion And Amortization Stock-compensation expense Allocated Share Based Compensation Expense Lease incentives Lease Incentives Premiums And Discounts Net Other Other Noncash Income Expense Changes in operating assets and liabilities: Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Inventories Increase Decrease In Inventories Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued expenses Increase Decrease In Accrued Liabilities Deferred revenue Increase Decrease In Deferred Revenue Deferred rent Increase Decrease In Deferred Rent Credit Noncurrent Net cash used in operating activities Net Cash Provided By Used In Operating Activities Continuing Operations Cash flows from investing activities: Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract] Capital expenditures Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Continuing Operations Cash flows from financing activities: Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract] Repayment of obligations under capital lease Repayments Of Long Term Capital Lease Obligations Payments made for employee restricted stock tax withholdings Payments Related To Tax Withholding For Share Based Compensation Net cash used in financing activities Net Cash Provided By Used In Financing Activities Continuing Operations Net decrease in cash Cash And Cash Equivalents Period Increase Decrease Cash at beginning of period Cash at end of period Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Interest paid Interest Paid Income taxes paid Income Taxes Paid Supplemental disclosures of non-cash activities: Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Changes in accrued capital expenditures Increase Decrease In Accrued Liabilities And Other Operating Liabilities Advanced billings Increase Decrease In Billing In Excess Of Cost Of Earnings Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business and Basis of Presentation Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Inventory Disclosure [Abstract] Inventories Inventory Disclosure [Text Block] Property Plant And Equipment [Abstract] Property, Plant and Equipment, Net Property Plant And Equipment Disclosure [Text Block] Payables And Accruals [Abstract] Accrued Expenses Accounts Payable And Accrued Liabilities Disclosure [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Deferred rent disclosure. Other Liabilities Disclosure [Abstract] Deferred Rent Deferred Rent Disclosure [Text Block] Net Loss Per Share Earnings Per Share [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Nature of business. Nature of Business Nature Of Business Policy [Text Block] Unaudited Interim Financial Information Basis Of Accounting Policy Policy [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Use of Estimates Use Of Estimates Cash and Cash Equivalents Cash And Cash Equivalents Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Product revenue. Product Revenue Product Revenue Policy [Text Block] Research revenue. Research Services Revenue Research Revenue Policy [Text Block] Stock-based Compensation Compensation Related Costs Policy [Text Block] Earnings per Share Earnings Per Share Policy [Text Block] Segments Segment Reporting Policy Policy [Text Block] Warranty Costs Standard Product Warranty Policy Recently Issued Accounting Standards New Accounting Pronouncements Policy Policy [Text Block] Summary of Stock Based Compensation Included in Cost of Sales or Operating Expenses Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Schedule of Total Revenues, Based on Shipment Destination or Research Services Location Revenue From External Customers By Geographic Areas Table [Text Block] Schedule of Inventories Schedule Of Inventory Current Table [Text Block] Summary of Property, Plant and Equipment Property Plant And Equipment [Text Block] Schedule of Accrued Expenses Schedule Of Accrued Liabilities Table [Text Block] Schedule of deferred rent. Summary of Deferred Rent Schedule Of Deferred Rent Table [Text Block] Computation of Basic and Diluted Net Loss Per Share Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Summary of Potentially Dilutive Common Shares Excluded from Computation of Diluted Net Loss Per Share Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Number of subsidiaries. Number of Subsidiaries Number Of Subsidiaries Summary of significant accounting policies. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand fourteen equity plan. 2014 Equity Plan [Member] Two Thousand Fourteen Equity Plan [Member] Award Type Award Type [Axis] Equity Award Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted Stock Units [Member] Restricted Stock Units R S U [Member] Non qualified stock options. Non-Qualified Stock Options [Member] Non Qualified Stock Options [Member] 2001 equity incentive plan. 2001 Equity Incentive Plan [Member] Two Thousand One Equity Incentive Plan [Member] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] Accounting standards update 2016-09. ASU 2016-09 [Member] Accounting Standards Update Two Thousand Sixteen Zero Nine [Member] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Stock-based awards granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Stock-based awards granted to purchase common stock Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Stock-based award vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Cost of Product Revenue [Member] Cost Of Sales [Member] Research and Development Expenses [Member] Research And Development Expense [Member] Sales and Marketing Expenses [Member] Selling And Marketing Expense [Member] General and Administrative Expenses [Member] General And Administrative Expense [Member] Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Total stock-based compensation Authorized for issuance, number of shares increased by Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized Increased number of shares authorized for grant Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares reserved for issuance Common Stock Capital Shares Reserved For Future Issuance Number of segment Number Of Operating Segments Regulatory Assets [Abstract] Regulatory Assets [Abstract] Schedule Of Segment Reporting Information By Segment [Table] Schedule Of Segment Reporting Information By Segment [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] U.S. [Member] UNITED STATES International. International [Member] International [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Revenue Standard product warranty period. Standard product warranty period Standard Product Warranty Period Warranty expense Standard Product Warranty Accrual Period Increase Decrease Cumulative effect adjustment to equity New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1 Raw materials Inventory Raw Materials Net Of Reserves Finished goods Inventory Finished Goods Net Of Reserves Total Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Construction in Progress [Member] Construction In Progress [Member] Buildings [Member] Building [Member] Machinery and Equipment [Member] Machinery And Equipment [Member] Computer Equipment And Software [Member] Computer Equipment and Software [Member] Computer Equipment And Software [Member] Range Range [Axis] Range Range [Member] EX-101.PRE 11 aspn-20170331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2017	May 01, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2017
Document Fiscal Period Focus	Q1
Trading Symbol	ASPN
Entity Registrant Name	ASPEN AEROGELS INC
Entity Central Index Key	0001145986
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		23,508,417

XML 13 R2.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 11,228	$ 18,086
Accounts receivable, net of allowances of $83 and $93	17,248	17,535
Inventories	15,132	12,868
Prepaid expenses and other current assets	1,192	1,697
Total current assets	44,800	50,186
Property, plant and equipment, net	82,719	84,394
Other long-term assets	97	89
Total assets	127,616	134,669
Current liabilities:
Accounts payable	14,169	13,065
Accrued expenses	4,112	3,987
Deferred revenue	789	1,043
Capital leases, current portion	20	35
Total current liabilities	19,090	18,130
Capital leases, excluding current portion		4
Deferred rent	1,082	971
Total liabilities	20,172	19,105
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock, $0.00001 par value; 5,000,000 shares authorized, no shares issued and outstanding at March 31, 2017 and December 31, 2016
Common stock, $0.00001 par value; 125,000,000 shares authorized, 23,508,417 and 23,369,838 shares issued and outstanding at March 31, 2017 and December 31, 2016, respectively	0	0
Additional paid-in capital	534,346	533,088
Accumulated deficit	(426,902)	(417,524)
Total stockholders’ equity	107,444	115,564
Total liabilities and stockholders’ equity	$ 127,616	$ 134,669

XML 14 R3.htm IDEA: XBRL DOCUMENT

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Allowance for doubtful accounts	$ 83	$ 93
Preferred stock, par value	$ 0.00001	$ 0.00001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.00001	$ 0.00001
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	23,508,417	23,369,838
Common stock, shares outstanding	23,508,417	23,369,838

XML 15 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Product	$ 22,326	$ 32,286
Research services	676	535
Total revenue	23,002	32,821
Cost of revenue:
Product	20,470	25,992
Research services	311	302
Gross profit	2,221	6,527
Operating expenses:
Research and development	1,576	1,310
Sales and marketing	3,110	3,062
General and administrative	6,587	3,913
Total operating expenses	11,273	8,285
Loss from operations	(9,052)	(1,758)
Interest expense, net	(26)	(39)
Total interest expense, net	(26)	(39)
Net loss	$ (9,078)	$ (1,797)
Net loss per share:
Basic and diluted	$ (0.39)	$ (0.08)
Weighted-average common shares outstanding:
Basic and diluted	23,257,541	23,063,471

XML 16 R5.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net loss	$ (9,078)	$ (1,797)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,676	2,410
Stock-compensation expense	1,244	1,370
Lease incentives	(22)
Other	(1)	(13)
Changes in operating assets and liabilities:
Accounts receivable	442	(2,291)
Inventories	(2,264)	393
Prepaid expenses and other assets	497	966
Accounts payable	2,238	1,508
Accrued expenses	125	(2,203)
Deferred revenue	(254)	(542)
Deferred rent	(22)	(15)
Net cash used in operating activities	(4,419)	(214)
Cash flows from investing activities:
Capital expenditures	(2,146)	(3,128)
Net cash used in investing activities	(2,146)	(3,128)
Cash flows from financing activities:
Repayment of obligations under capital lease	(7)	(23)
Payments made for employee restricted stock tax withholdings	(286)	(82)
Net cash used in financing activities	(293)	(105)
Net decrease in cash	(6,858)	(3,447)
Cash at beginning of period	18,086	32,804
Cash at end of period	11,228	29,357
Supplemental disclosures of cash flow information:
Interest paid	40	52
Supplemental disclosures of non-cash activities:
Changes in accrued capital expenditures	$ (1,134)	484
Advanced billings		$ 292

XML 17 R6.htm IDEA: XBRL DOCUMENT

Description of Business and Basis of Presentation	3 Months Ended
Description of Business and Basis of Presentation	Mar. 31, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Description of Business and Basis of Presentation	(1) Description of Business and Basis of Presentation Nature of Business Aspen Aerogels, Inc. (the Company) is an aerogel technology company that designs, develops and manufactures innovative, high-performance aerogel insulation used primarily in the energy infrastructure and building materials markets. The Company also conducts research and development related to aerogel technology supported by funding from several agencies of the U.S. government and other institutions in the form of research and development contracts. The Company maintains its corporate offices in Northborough, Massachusetts. The Company has three wholly owned subsidiaries: Aspen Aerogels Rhode Island, LLC, Aspen Aerogels Germany, GmbH and Aspen Aerogels Georgia, LLC. Unaudited Interim Financial Information The accompanying unaudited interim consolidated financial statements include the accounts of the Company and have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes in our Annual Report on Form 10-K for the year ended December 31, 2016 (the Annual Report), filed with the Securities and Exchange Commission on March 2, 2017. In the opinion of the Company’s management, the unaudited interim consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and include all adjustments that are of a normal recurring nature and necessary for the fair statement of the Company’s financial position as of March 31, 2017 and the results of its operations for the three months ended March 31, 2017 and 2016 and the cash flows for the three month periods then ended. The Company has evaluated events through the date of this filing. The results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017 or any other period. There have been no changes to the Company’s significant accounting policies described in the Annual Report that have had a material impact on the Company’s consolidated financial statements and notes thereto.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Significant Accounting Policies

(2) Significant Accounting Policies

Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Revenue Recognition

Product Revenue

Product revenue is recognized upon transfer of title and risk of loss, which is upon shipment or delivery. The Company’s customary shipping terms are free on board (FOB) shipping point.

Research Services Revenue

Stock-based Compensation

	Three Months Ended
	March 31,
	2017		2016
	(In thousands)
Cost of product revenue	$	204	$	192
Research and development expenses		138		140
Sales and marketing expenses		268		261
General and administrative expenses		634		777
Total stock-based compensation	$	1,244	$	1,370

Earnings per Share

Segments

Information about the Company’s total revenues, based on shipment destination or services location, is presented in the following table:

	Three Months Ended
	March 31,
	2017		2016
	(In thousands)
Revenue:
U.S.	$	9,130	$	11,413
International		13,872		21,408
Total	$	23,002	$	32,821

Warranty Costs

Recently Issued Accounting Standards

XML 19 R8.htm IDEA: XBRL DOCUMENT

Inventories

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Inventories

(3) Inventories

Inventories consist of the following:

	March 31,		December 31,
	2017		2016
	(In thousands)
Raw materials	$	3,556	$	3,511
Finished goods		11,576		9,357
Total	$	15,132	$	12,868

XML 20 R9.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net

3 Months Ended

Mar. 31, 2017

Property Plant And Equipment [Abstract]

Property, Plant and Equipment, Net

(4) Property, Plant and Equipment, Net

Property, plant and equipment consist of the following:

	March 31,			December 31,			Useful
	2017			2016			life
	(In thousands)
Construction in progress	$	11,216		$	11,139			—
Buildings		23,929			23,901		30 years
Machinery and equipment		114,370			113,659		3-10 years
Computer equipment and software		7,817			7,679		3 years
Total		157,332			156,378
Accumulated depreciation		(74,613	)		(71,984	)
Property, plant and equipment, net	$	82,719		$	84,394

Depreciation expense was $2.7 million and $2.4 million for the three months ended March 31, 2017 and 2016, respectively.

XML 21 R10.htm IDEA: XBRL DOCUMENT

Accrued Expenses

3 Months Ended

Mar. 31, 2017

Payables And Accruals [Abstract]

Accrued Expenses

(5) Accrued Expenses

Accrued expenses consist of the following:

	March 31,		December 31,
	2017		2016
	(In thousands)
Employee compensation	$	2,661	$	2,796
Other accrued expenses		1,451		1,191
Total	$	4,112	$	3,987

XML 22 R11.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies	3 Months Ended
Commitments and Contingencies	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(6) Commitments and Contingencies Customer Supply Agreement During 2016, the Company entered into a supply agreement and a side agreement (together, the Supply Agreement) and a joint development agreement (the JDA) with BASF SE (BASF). Pursuant to the Supply Agreement, the Company will sell exclusively to BASF the Company’s Spaceloft ^® A2 product at annual volumes to be specified by BASF, subject to certain volume limits. The Supply Agreement will terminate on December 31, 2027. Upon expiration of the Supply Agreement, the Company will be subject to a post-termination supply commitment for an additional two years. The JDA is designed to facilitate the collaboration between the parties on the development and commercialization of new products. In addition, under the terms of the Supply Agreement, BASF will make a non-interest bearing prepayment to the Company in the aggregate amount of $22 million during the construction of the Company’s planned manufacturing facility in Statesboro, Georgia (Plant Two), subject to the Company’s prior satisfaction of certain preconditions, including securing a debt commitment from a third party lender for at least $30 million. BASF is obligated to pay the prepayment to the Company in eight equal consecutive quarterly installments commencing on the first day of the calendar quarter following the date on which the preconditions are met. Once commenced, BASF’s obligation to make such quarterly payments shall be subject to postponement in the event of delays of three months or more in the projected date of completion of Plant Two by a commensurate number of months. After October 1, 2018, the Company will, at BASF’s instruction, credit up to 25.3% of any amounts invoiced by the Company for Spaceloft ^® A2 product sold to BASF against the prepayment balance. However, BASF has no obligation to purchase products under the Supply Agreement. If any of the prepayment remains uncredited against amounts invoiced by the Company as of September 30, 2023, BASF may request that the Company repay the uncredited amount to BASF in four equal quarterly installments beginning on December 31, 2023. The repayment obligation will be secured by a security interest in real estate, plant and equipment at the Company’s Rhode Island and Georgia manufacturing facilities. As of March 31, 2017, the Company anticipates that the impact of constrained capital investment and low activity levels in the global energy markets will continue through 2017. With this view of the market, the Company has elected to temporarily delay the board approved Plant Two project and its related financing to better align the capacity expansion with the Company’s assessment of demand for the 2018 to 2020 period. As a result, the Company has yet to fulfill the prepayment preconditions and commencement of the quarterly prepayments from BASF will be delayed until the preconditions are satisfied. Revolving Line of Credit The Company entered into an Amended and Restated Loan and Security Agreement with Silicon Valley Bank (Loan Agreement), on August 31, 2014, which has been subsequently amended from time to time. On January 27, 2017, the Loan Agreement was amended to extend the maturity date of the revolving credit facility to January 28, 2018. Under the Loan Agreement, the Company may borrow up to $20 million subject to compliance with certain covenants and borrowing base limitations. At the Company’s election, the interest rate applicable to borrowings may be based on the prime rate or LIBOR. Prime rate-based rates vary from prime rate plus 0.75% per annum to prime rate plus 1.75% per annum, while LIBOR-based rates vary from LIBOR plus 3.75% per annum to LIBOR plus 4.25% per annum. In addition, the Company is required to pay a monthly unused line fee of 0.5% per annum of the average unused portion of the facility. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in all assets of the Company, including those at the East Providence facility, except for certain exclusions. At March 31, 2017 and December 31, 2016, the Company had no amounts drawn on the revolving credit facility. Under the Loan Agreement, the Company is required to comply with both non-financial and financial covenants, including minimum Adjusted EBITDA and minimum Adjusted Quick Ratio, as defined. At March 31, 2017, the Company was in compliance with all such financial covenants. The Company has been required to provide its landlord for its Northborough, Massachusetts facility with letters of credit securing certain obligations. As of January 31, 2017, these obligations were released by the landlord. In addition, the Company has been required to provide certain customers with letters of credit securing obligations under commercial contracts. The Company had outstanding letters of credit backed by the revolving credit facility of $2.4 million and $2.7 million at March 31, 2017 and December 31, 2016, respectively, which reduce the funds otherwise available to the Company under the facility. Based on the available borrowing base, the effective amount available to the Company under the revolving credit facility at March 31, 2017 was $9.7 million after consideration of the $2.4 million of outstanding letters of credit. Litigation The Company is, from time to time, a party to litigation that arises in the normal course of its business operations. See Part II, Item 1 (“Legal Proceedings”) of this Quarterly Report on Form 10-Q for a description of certain of the Company’s current legal proceedings. The Company is not presently a party to any litigation for which it believes a loss is probable requiring an amount to be accrued or a possible loss contingency requiring disclosure.

XML 23 R12.htm IDEA: XBRL DOCUMENT

Deferred Rent

3 Months Ended

Mar. 31, 2017

Other Liabilities Disclosure [Abstract]

Deferred Rent

(7) Deferred Rent

Lease incentives for allowances for qualified leasehold improvements received from the landlord are amortized on a straight-line basis over the lease term. These improvements and the funding received from the landlord are recorded as fixed asset additions and a deferred rent liability on the consolidated balance sheet. The deferred rent liability is being amortized as a reduction to rent expense over the life of the lease.

Deferred rent consists of the following:

	March 31,			December 31,
	2017			2016
	(In thousands)
Deferred rent	$	1,251		$	1,125
Current maturities of deferred rent		(169	)		(154	)
Deferred rent, less current maturities	$	1,082		$	971

XML 24 R13.htm IDEA: XBRL DOCUMENT

Net Loss Per Share

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Net Loss Per Share

(8) Net Loss Per Share

The computation of basic and diluted net loss per share consists of the following:

	Three Months Ended
	March 31,
	2017			2016
	(In thousands, except share and per share data)
Numerator:
Net loss	$	(9,078	)	$	(1,797	)
Denominator:
Weighted average shares outstanding, basic and diluted		23,257,541			23,063,471
Net loss per share, basic and diluted	$	(0.39	)	$	(0.08	)

Potentially dilutive common shares that were excluded from the computation of diluted net loss per share because they were anti-dilutive consist of the following:

	Three Months Ended
	March 31,
	2017		2016
Common stock options		2,382,710		1,952,879
Restricted common stock units		954,928		759,510
Common stock warrants		115		131
Restricted common stock awards		153,277		132,130
Total		3,491,030		2,844,650

XML 25 R14.htm IDEA: XBRL DOCUMENT

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	(9) Income Taxes The Company incurred net operating losses and recorded a full valuation allowance against net deferred tax assets for all periods presented. Accordingly, the Company has not recorded a provision for federal or state income taxes.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Description of Business and Basis of Presentation (Policies)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Nature of Business

Unaudited Interim Financial Information

The results of operations for the three months ended March 31, 2017 are not necessarily indicative of the results to be expected for the year ending December 31, 2017 or any other period.

Principles of Consolidation

Use of Estimates

Cash and Cash Equivalents

Revenue Recognition

Product Revenue

Product revenue is recognized upon transfer of title and risk of loss, which is upon shipment or delivery. The Company’s customary shipping terms are free on board (FOB) shipping point.

Research Services Revenue

Stock-based Compensation

	Three Months Ended
	March 31,
	2017		2016
	(In thousands)
Cost of product revenue	$	204	$	192
Research and development expenses		138		140
Sales and marketing expenses		268		261
General and administrative expenses		634		777
Total stock-based compensation	$	1,244	$	1,370

Earnings per Share

Segments

Information about the Company’s total revenues, based on shipment destination or services location, is presented in the following table:

	Three Months Ended
	March 31,
	2017		2016
	(In thousands)
Revenue:
U.S.	$	9,130	$	11,413
International		13,872		21,408
Total	$	23,002	$	32,821

Warranty Costs

Recently Issued Accounting Standards

XML 27 R16.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2017

Accounting Policies [Abstract]

Summary of Stock Based Compensation Included in Cost of Sales or Operating Expenses

Stock-based compensation is included in cost of sales or operating expenses, as applicable, and consists of the following:

	Three Months Ended
	March 31,
	2017		2016
	(In thousands)
Cost of product revenue	$	204	$	192
Research and development expenses		138		140
Sales and marketing expenses		268		261
General and administrative expenses		634		777
Total stock-based compensation	$	1,244	$	1,370

Schedule of Total Revenues, Based on Shipment Destination or Research Services Location

Information about the Company’s total revenues, based on shipment destination or services location, is presented in the following table:

	Three Months Ended
	March 31,
	2017		2016
	(In thousands)
Revenue:
U.S.	$	9,130	$	11,413
International		13,872		21,408
Total	$	23,002	$	32,821

XML 28 R17.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

3 Months Ended

Mar. 31, 2017

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:

	March 31,		December 31,
	2017		2016
	(In thousands)
Raw materials	$	3,556	$	3,511
Finished goods		11,576		9,357
Total	$	15,132	$	12,868

XML 29 R18.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2017

Property Plant And Equipment [Abstract]

Summary of Property, Plant and Equipment

Property, plant and equipment consist of the following:

	March 31,			December 31,			Useful
	2017			2016			life
	(In thousands)
Construction in progress	$	11,216		$	11,139			—
Buildings		23,929			23,901		30 years
Machinery and equipment		114,370			113,659		3-10 years
Computer equipment and software		7,817			7,679		3 years
Total		157,332			156,378
Accumulated depreciation		(74,613	)		(71,984	)
Property, plant and equipment, net	$	82,719		$	84,394

XML 30 R19.htm IDEA: XBRL DOCUMENT

Accrued Expenses (Tables)

3 Months Ended

Mar. 31, 2017

Payables And Accruals [Abstract]

Schedule of Accrued Expenses

Accrued expenses consist of the following:

	March 31,		December 31,
	2017		2016
	(In thousands)
Employee compensation	$	2,661	$	2,796
Other accrued expenses		1,451		1,191
Total	$	4,112	$	3,987

XML 31 R20.htm IDEA: XBRL DOCUMENT

Deferred Rent (Tables)

3 Months Ended

Mar. 31, 2017

Other Liabilities Disclosure [Abstract]

Summary of Deferred Rent

Deferred rent consists of the following:

	March 31,			December 31,
	2017			2016
	(In thousands)
Deferred rent	$	1,251		$	1,125
Current maturities of deferred rent		(169	)		(154	)
Deferred rent, less current maturities	$	1,082		$	971

XML 32 R21.htm IDEA: XBRL DOCUMENT

Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2017

Earnings Per Share [Abstract]

Computation of Basic and Diluted Net Loss Per Share

The computation of basic and diluted net loss per share consists of the following:

	Three Months Ended
	March 31,
	2017			2016
	(In thousands, except share and per share data)
Numerator:
Net loss	$	(9,078	)	$	(1,797	)
Denominator:
Weighted average shares outstanding, basic and diluted		23,257,541			23,063,471
Net loss per share, basic and diluted	$	(0.39	)	$	(0.08	)

Summary of Potentially Dilutive Common Shares Excluded from Computation of Diluted Net Loss Per Share

Potentially dilutive common shares that were excluded from the computation of diluted net loss per share because they were anti-dilutive consist of the following:

	Three Months Ended
	March 31,
	2017		2016
Common stock options		2,382,710		1,952,879
Restricted common stock units		954,928		759,510
Common stock warrants		115		131
Restricted common stock awards		153,277		132,130
Total		3,491,030		2,844,650

XML 33 R22.htm IDEA: XBRL DOCUMENT

Description of Business and Basis of Presentation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017 Subsidiary
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Number of Subsidiaries	3

XML 34 R23.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Additional Information (Detail) $ in Millions		3 Months Ended
	Jan. 02, 2017 shares	Mar. 31, 2017 USD ($) Segment shares	Jan. 01, 2017 USD ($)
Summary Of Significant Accounting Policies [Line Items]
Number of segment \| Segment		1
Standard product warranty period		1 year
Warranty expense \| $		$ 0.9
ASU 2016-09 [Member]
Summary Of Significant Accounting Policies [Line Items]
Cumulative effect adjustment to equity \| $			$ 0.3
2014 Equity Plan [Member]
Summary Of Significant Accounting Policies [Line Items]
Authorized for issuance, number of shares increased by	467,396
Increased number of shares authorized for grant	6,536,597	2,485,081
Shares reserved for issuance		3,244,691
2014 Equity Plan [Member] \| Restricted Stock Units [Member]
Summary Of Significant Accounting Policies [Line Items]
Stock-based awards granted		481,373
Stock-based award vesting period		3 years
2014 Equity Plan [Member] \| Non-Qualified Stock Options [Member]
Summary Of Significant Accounting Policies [Line Items]
Stock-based awards granted to purchase common stock		320,571
Stock-based award vesting period		3 years
2001 Equity Incentive Plan [Member]
Summary Of Significant Accounting Policies [Line Items]
Shares reserved for issuance		92,947

XML 35 R24.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Summary of Stock Based Compensation Included in Cost of Sales or Operating Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 1,244	$ 1,370
Cost of Product Revenue [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	204	192
Research and Development Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	138	140
Sales and Marketing Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	268	261
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total stock-based compensation	$ 634	$ 777

XML 36 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies - Schedule of Total Revenues, Based on Shipment Destination or Research Services Location (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenue	$ 23,002	$ 32,821
U.S. [Member]
Segment Reporting Information [Line Items]
Revenue	9,130	11,413
International [Member]
Segment Reporting Information [Line Items]
Revenue	$ 13,872	$ 21,408

XML 37 R26.htm IDEA: XBRL DOCUMENT

Inventories - Schedule of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 3,556	$ 3,511
Finished goods	11,576	9,357
Total	$ 15,132	$ 12,868

XML 38 R27.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net - Summary of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Property Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 157,332	$ 156,378
Accumulated depreciation	(74,613)	(71,984)
Property, plant and equipment, net	82,719	84,394
Construction in Progress [Member]
Property Plant and Equipment [Line Items]
Property, plant and equipment, gross	11,216	11,139
Buildings [Member]
Property Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 23,929	23,901
Property, plant and equipment, Useful life	30 years
Machinery and Equipment [Member]
Property Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 114,370	113,659
Machinery and Equipment [Member] \| Minimum [Member]
Property Plant and Equipment [Line Items]
Property, plant and equipment, Useful life	3 years
Machinery and Equipment [Member] \| Maximum [Member]
Property Plant and Equipment [Line Items]
Property, plant and equipment, Useful life	10 years
Computer Equipment and Software [Member]
Property Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 7,817	$ 7,679
Property, plant and equipment, Useful life	3 years

XML 39 R28.htm IDEA: XBRL DOCUMENT

Property, Plant and Equipment, Net - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Property Plant and Equipment [Line Items]
Depreciation expense	$ 2,700	$ 2,400
Property, plant and equipment, gross	157,332		$ 156,378
Construction in Progress [Member]
Property Plant and Equipment [Line Items]
Property, plant and equipment, gross	11,216		11,139
Statesboro, Georgia [Member] \| Construction in Progress [Member]
Property Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 7,200		$ 7,200

XML 40 R29.htm IDEA: XBRL DOCUMENT

Accrued Expenses - Schedule of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Accrued Liabilities Current [Abstract]
Employee compensation	$ 2,661	$ 2,796
Other accrued expenses	1,451	1,191
Total	$ 4,112	$ 3,987

XML 41 R30.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Additional Information (Detail)		3 Months Ended
	Jan. 27, 2017	Mar. 31, 2017 USD ($) Installment	Dec. 31, 2016 USD ($)
Silicon Valley Bank Credit Facility [Member] \| Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Maximum increased borrowing amount		$ 20,000,000
Interest rate description		The interest rate applicable to borrowings may be based on the prime rate or LIBOR. Prime rate-based rates vary from prime rate plus 0.75% per annum to prime rate plus 1.75% per annum, while LIBOR-based rates vary from LIBOR plus 3.75% per annum to LIBOR plus 4.25% per annum.
Percentage of unused line fee		0.50%
Silicon Valley Bank Credit Facility [Member] \| Loan Agreement [Member] \| Revolving Credit Facility [Member]
Commitments And Contingencies [Line Items]
Extended maturity date	Jan. 28, 2018
Line of credit facility amount withdrawn		$ 0	$ 0
Letters of credit outstanding		2,400,000	$ 2,700,000
Line of credit facility borrowing capacity		$ 9,700,000
Minimum [Member] \| Prime Rate [Member] \| Silicon Valley Bank Credit Facility [Member] \| Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Additional interest rate per annum		0.75%
Minimum [Member] \| LIBOR Rate [Member] \| Silicon Valley Bank Credit Facility [Member] \| Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Additional interest rate per annum		3.75%
Maximum [Member] \| Prime Rate [Member] \| Silicon Valley Bank Credit Facility [Member] \| Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Additional interest rate per annum		1.75%
Maximum [Member] \| LIBOR Rate [Member] \| Silicon Valley Bank Credit Facility [Member] \| Loan Agreement [Member]
Commitments And Contingencies [Line Items]
Additional interest rate per annum		4.25%
Supply and Joint Development Agreement [Member] \| BASF [Member]
Commitments And Contingencies [Line Items]
Supply agreement termination date		Dec. 31, 2027
Non-interest bearing prepayment, aggregate amount		$ 22,000,000
Number of quarterly installments \| Installment		8
Supply and Joint Development Agreement [Member] \| BASF [Member] \| Maximum [Member]
Commitments And Contingencies [Line Items]
Credit limit percentage on prepayment balance		25.30%
Supply and Joint Development Agreement [Member] \| BASF [Member] \| Third Party Lender [Member] \| Minimum [Member] \| Plant Two [Member]
Commitments And Contingencies [Line Items]
Secured debt, commitment		$ 30,000,000

XML 42 R31.htm IDEA: XBRL DOCUMENT

Deferred Rent - Additional Information (Detail) $ in Millions	Mar. 31, 2017 USD ($)
Other Liabilities Disclosure [Abstract]
Deferred lease incentives	$ 0.8
Straight-line rental obligations	$ 0.5

XML 43 R32.htm IDEA: XBRL DOCUMENT

Deferred Rent - Summary of Deferred Rent (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Deferred Revenue And Credits [Abstract]
Deferred rent	$ 1,251	$ 1,125
Current maturities of deferred rent	(169)	(154)
Deferred rent, less current maturities	$ 1,082	$ 971

XML 44 R33.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Numerator:
Net loss	$ (9,078)	$ (1,797)
Denominator:
Weighted average shares outstanding, basic and diluted	23,257,541	23,063,471
Net loss per share, basic and diluted	$ (0.39)	$ (0.08)

XML 45 R34.htm IDEA: XBRL DOCUMENT

Net Loss Per Share - Summary of Potentially Dilutive Common Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) - shares	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive Securities	3,491,030	2,844,650
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive Securities	2,382,710	1,952,879
Restricted Common Stock Units [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive Securities	954,928	759,510
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive Securities	115	131
Restricted Common Stock Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive Securities	153,277	132,130

EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.7.0.1 html 60 147 1 false 31 0 false 7 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aerogel.com/20170331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.aerogel.com/20170331/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.aerogel.com/20170331/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://www.aerogel.com/20170331/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Cash Flows Sheet http://www.aerogel.com/20170331/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 5 false false R6.htm 100050 - Disclosure - Description of Business and Basis of Presentation Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentation Description of Business and Basis of Presentation Notes 6 false false R7.htm 100060 - Disclosure - Significant Accounting Policies Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Inventories Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureInventories Inventories Notes 8 false false R9.htm 100080 - Disclosure - Property, Plant and Equipment, Net Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosurePropertyPlantAndEquipmentNet Property, Plant and Equipment, Net Notes 9 false false R10.htm 100090 - Disclosure - Accrued Expenses Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses Notes 10 false false R11.htm 100100 - Disclosure - Commitments and Contingencies Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 11 false false R12.htm 100110 - Disclosure - Deferred Rent Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureDeferredRent Deferred Rent Notes 12 false false R13.htm 100120 - Disclosure - Net Loss Per Share Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureNetLossPerShare Net Loss Per Share Notes 13 false false R14.htm 100130 - Disclosure - Income Taxes Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 14 false false R15.htm 100140 - Disclosure - Description of Business and Basis of Presentation (Policies) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationPolicies Description of Business and Basis of Presentation (Policies) Policies http://www.aerogel.com/20170331/taxonomy/role/DisclosureSignificantAccountingPolicies 15 false false R16.htm 100150 - Disclosure - Significant Accounting Policies (Tables) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureSignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://www.aerogel.com/20170331/taxonomy/role/DisclosureSignificantAccountingPolicies 16 false false R17.htm 100160 - Disclosure - Inventories (Tables) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureInventoriesTables Inventories (Tables) Tables http://www.aerogel.com/20170331/taxonomy/role/DisclosureInventories 17 false false R18.htm 100170 - Disclosure - Property, Plant and Equipment, Net (Tables) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosurePropertyPlantAndEquipmentNetTables Property, Plant and Equipment, Net (Tables) Tables http://www.aerogel.com/20170331/taxonomy/role/DisclosurePropertyPlantAndEquipmentNet 18 false false R19.htm 100180 - Disclosure - Accrued Expenses (Tables) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://www.aerogel.com/20170331/taxonomy/role/DisclosureAccruedExpenses 19 false false R20.htm 100190 - Disclosure - Deferred Rent (Tables) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureDeferredRentTables Deferred Rent (Tables) Tables http://www.aerogel.com/20170331/taxonomy/role/DisclosureDeferredRent 20 false false R21.htm 100200 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.aerogel.com/20170331/taxonomy/role/DisclosureNetLossPerShare 21 false false R22.htm 100210 - Disclosure - Description of Business and Basis of Presentation - Additional Information (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureDescriptionOfBusinessAndBasisOfPresentationAdditionalInformationDetail Description of Business and Basis of Presentation - Additional Information (Detail) Details 22 false false R23.htm 100220 - Disclosure - Significant Accounting Policies - Additional Information (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetail Significant Accounting Policies - Additional Information (Detail) Details 23 false false R24.htm 100230 - Disclosure - Significant Accounting Policies - Summary of Stock Based Compensation Included in Cost of Sales or Operating Expenses (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureSignificantAccountingPoliciesSummaryOfStockBasedCompensationIncludedInCostOfSalesOrOperatingExpensesDetail Significant Accounting Policies - Summary of Stock Based Compensation Included in Cost of Sales or Operating Expenses (Detail) Details 24 false false R25.htm 100240 - Disclosure - Significant Accounting Policies - Schedule of Total Revenues, Based on Shipment Destination or Research Services Location (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureSignificantAccountingPoliciesScheduleOfTotalRevenuesBasedOnShipmentDestinationOrResearchServicesLocationDetail Significant Accounting Policies - Schedule of Total Revenues, Based on Shipment Destination or Research Services Location (Detail) Details 25 false false R26.htm 100250 - Disclosure - Inventories - Schedule of Inventories (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureInventoriesScheduleOfInventoriesDetail Inventories - Schedule of Inventories (Detail) Details 26 false false R27.htm 100260 - Disclosure - Property, Plant and Equipment, Net - Summary of Property, Plant and Equipment (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosurePropertyPlantAndEquipmentNetSummaryOfPropertyPlantAndEquipmentDetail Property, Plant and Equipment, Net - Summary of Property, Plant and Equipment (Detail) Details 27 false false R28.htm 100270 - Disclosure - Property, Plant and Equipment, Net - Additional Information (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosurePropertyPlantAndEquipmentNetAdditionalInformationDetail Property, Plant and Equipment, Net - Additional Information (Detail) Details 28 false false R29.htm 100280 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureAccruedExpensesScheduleOfAccruedExpensesDetail Accrued Expenses - Schedule of Accrued Expenses (Detail) Details 29 false false R30.htm 100290 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 30 false false R31.htm 100300 - Disclosure - Deferred Rent - Additional Information (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureDeferredRentAdditionalInformationDetail Deferred Rent - Additional Information (Detail) Details 31 false false R32.htm 100310 - Disclosure - Deferred Rent - Summary of Deferred Rent (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureDeferredRentSummaryOfDeferredRentDetail Deferred Rent - Summary of Deferred Rent (Detail) Details 32 false false R33.htm 100320 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetail Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Detail) Details 33 false false R34.htm 100330 - Disclosure - Net Loss Per Share - Summary of Potentially Dilutive Common Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) Sheet http://www.aerogel.com/20170331/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveCommonSharesExcludedFromComputationOfDilutedNetLossPerShareDetail Net Loss Per Share - Summary of Potentially Dilutive Common Shares Excluded from Computation of Diluted Net Loss Per Share (Detail) Details 34 false false All Reports Book All Reports aspn-20170331.xml aspn-20170331.xsd aspn-20170331_cal.xml aspn-20170331_def.xml aspn-20170331_lab.xml aspn-20170331_pre.xml true true ZIP 52 0001564590-17-008901-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-17-008901-xbrl.zip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
Z M!6"+;FZ,U&>5>KUAAM;=CY)E5N=NR$A:\EB3N#_DM2;Q:$QBLW)YL>[MRZ,T MB;:*Y\NJ>!:AR2L)KED/L%Q4\"8<#$2,]059:]8&321 !6/G(=D./1'SG4O MXAS7NY'%F5#[]+TJ"ZJ*D6)Q1*#ID 4CA[(QW'-$$(<.QV,B:JQQK+W67_T9PJB.QQ^Y'P[5:(4AX,/_?'_]VGD2<=]Y=_WP MT7GXX+S"/UY7G;LDD@DV8@.HIDU17L23\'U'+ZMWK[3*DK M^!Y_=:X;6%C62]P8BZJR($B8[SR&?H(D!Y ZW,%2L*(K .N=$8%8 ;QW_N0N M+=>%Z9@(]#>.+T#V9-7Y-@4+:N% P($(6,R=,,@JM3JJ0&NC776^#U4Q81&I MNL*Z/.82*$58<\"8,PPE$R>#H?2[.)F"H+*TK+ 00..;\#:XZ?0&7$6Z34 MS1TA=9U;0 $,K(O5X@H0!*HU"59>3='A\1/G@:IURR)4\KA._&>)LP*/P."1 M*X!._YLM-0 ITP21!U3,^#;'<<5) "Y=[QF((V=3F.2!2#M@/T"B8<@ 5H4J M0,: :D9:8ACQ(1L16K7XI5PA%.)9#X;L(;W8 $TRE1-NY-6$/:5M%#$+E8LU M7-.$<;TRQJ^HJK#S[2E\79*AF;-$ O@3;UA)G$3#E$HPG$Q@S!UTO6SJRSR:4#ZH>T&-*[6DV!/%7O.=QGXTTVQ?J MG0,!!B$ J%\'+8"C ;K5JKITX<[G*1MDO(1JF>G%@#N(+P<)*55X2XU]0)KD MNHMD_^K&(:Y0E?6^F#0&%63F":J*7+HKC@N.A(@=,*1 L$:KVOP[(@P'4&H" M7W\,A:L,7W$"E)6MFV,)7F7F%+ >0]C'1:[#@ E<7G7^(WP"]HJTRNPS"3@; MX^%A$KGP@&?FI:"'QU5OU;E5F-!B5Y@RX@,$!3Y6^ /LI, M0ALCGG_@PUC; M_!K9_*:&>@!B'H&RX+1.%I>^)0#HE^+$2IVG2!+82"")M,*9H60Z'!@\T#IF MW/UH*J.?K[: PLS%0.VJ%L>TJB6-KZT2 !%QF![^!DF":R53S]ORP@Q0,>-0; >*C'QP8A^CO M4BR94*>*,.GU";2J\T\,"L"H2N=1 ,*TU*@ORX"C:')?Z74TF'PP!-#W 4/5QE.9%)R*0>9M1K@=&D#!U2WI#!KC9HSY."A>%4'*,>P:43B M3UGNB).(=A._2_Y_69^,&>C4+P:ME@* 'Q3,;O:I5-Y,[B1VN,(A( 34@O!G M. #*GX)X9BG1>4'*X^=D ^XYA%Z/2/M/P.^(L!O2CP>3#/@V,_X/G.N!ZA*# M?'.O5*[G? J9ZH?RD&KG8@@*C/\ NA.8POEOL H<8EH6_'!>T5=Y4J""]N$Z MZ26@T[4..DM;H2!7=S#* X]/HL4*8LQ":%B(*V- $PDX_#^ZF\Y_@OYFTSS2"I2/+22+&GQI6<6]"+0#YJ'(':+IU *L@Y3>2E$02$4$ ( M^@X4V*?;=U_OJ\Y=]N.I>CDB0_*(Z"+J%;X:^HFDO9B_YS9IB.HU ">;_*JQ M=^LSWB7F 9@)AAGSTC,U3'/.E(77SJJ-J:^!!U<,N4N!F20W2T1Y),=4G !, MG 0) N:C*NERXK1:=3H@F@D9^)VLQ],OP9P5@^>4(Y5C-8W4N8M5]$C'!(/T M=M'Q4I$A!Q <,?N_ Z@H/+5 &?04S M=>"WDA5,&5TG[Y"5#\@'6[]I5-GN>QB!I!&!%[&G(!7)F5IK60TUQL"DB$9* M"0%F^Y0ETAX1N''DO&3_RK13D0<&(A #X.AK[T]0]]A\Z-WMM_?7].G$LW\D MPOWAW"/'5C"D\7@7_4Q29TOYKJCD24^6]2=R*Z48I@![0 SV;(/7T"[]#&I!KYW!= M)7/[H'=B] 93XT?H],D+)LG7;):E MQ5(!+FB>:F%?+_M+Q2.I'2T1$U1&46\]@8^R-?U6R?@[*JU;-R1[I& MM;VMAG0P?>*J''P75BM5 [HG@>K\D0D_]1"*",\-3*YTWA7]A?S+LN>BZ,:[ M705%FGI88J+9")N##VJB>%G$':6]J&48#%S:&2DA'7Z;2\W#B'D^@2SUQ@J/ M'5"4(\ Z3401%=S1HHP]_.!G"%#I#Q@16\KI!(8:%[@EB22Y<*@Z.^"K!-@_ M$ALZ\2OVT1NWM)]Z#$<$UXC^8(_8V$3RM5.?:@3(TP.@ZOW MO,L!5]X]G]JPLG@^Y.Q(>TVV"[TF4W0Y]\L=GEAB>BF!YAZ35L#HQUS*#$+JSVE&!-L*VXM/FICJ2;'"2KD$^!8D2?5YIX ZQM1 M7);NLI-:2$=G.E6BQ51K#;531\*LG'5%\8AV.1;0?+E39"N3?+5VT%L"8@M\ M]XF(!_P% E4J*3P<7\6HQSU3]R:48=)B-1]W.02 TITJYPN4)R+QRR-5O"C M*0D Q(UB6(2W$C.1H9"\/%/*+^@\(H\OF%FQ(N8:I98DRBUDGKW4QXA*+ 9& M1QWV&Z4.)KIP>+Z7,I5Z_\Z1?8Z[TM_HE,CTSP5&"F2(,@PPE77W]'$%L$LE M>=SU M@:>5>.K9U:Y98%CK5J MJQC6E$5=6Y92"'\HH<#[$OITF^@LAVG[1-L^T;9/M.UL869A?N-Z,AT=E293 MBL:*D>UN8219;)]HJ\O,H)+M$VTZA4SO&V?[1.^543*YS0@17F*YUK6%-P; -/4W;9;1?"+5'&]%*EMLHHKK9>::S=*3*'$DC+H[J #M5C[99O M*)BQQV ;:.Y;EMHVT-QGZMD&FBOFO>OGEV9H2@-W8TTBU*[W)*P]VU.-:.W9 M/E//VK-5[5GKS Q-:>W9NO;LN-I FT^JT@YOQ?&QW)0[$8#O.*UE^U_N;<+> M]K\\U*R_[7^YP:V#VH5M";T/E#)&YUJ3:#1YK$FT)M&:Q!>0^K*]ZZ-:>V40 M;4/H33:$7J8R;[GK\P<688<>CASZ;4<"W=9P-GB\*]7N_\-CYA!67[[ 9 M,F(JI\&*-0!WII\FBP]FY<"Q0T029[7>L;JI2Z41/>$G6. Q@/53Q6ELRB+[ M5,'15@NTU0)MM4"C=F9L/2U[=]$,*GVC?L.?0^HW_ ';S!DK-/;^HGE7Z6TQ MK;VR2.8,IHV91X5YW_+T\\EE;R@;2;2IQ<;L!>396P"7E5K[P@P5 MN1]WD$TL-V8-F35DUI!90W;,AJQ>:5^:>C[5&K(E#9G=O-UABWU+,)>U-) MVFA6&JUVI76V;@5LF[0_2@FTYLUH\ECS=IC4L^9M9?-6.V]6SM9N\&#-FVD2 M:)LZFD6S+Q-=!C87C-L&5KN6MIUG*1=FG*T[
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